

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
12 January 2006 (12.01.2006)

PCT

(10) International Publication Number  
WO 2006/003134 A1(51) International Patent Classification<sup>7</sup>: C07K 1/14,  
1/20, 14/715

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

(21) International Application Number:

PCT/EP2005/053010

(22) International Filing Date: 27 June 2005 (27.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

04103047.9 29 June 2004 (29.06.2004) EP  
60/587,296 12 July 2004 (12.07.2004) US

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(U)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PURIFICATION OF IL-18 BINDING PROTEIN

(57) **Abstract:** The invention relates to a process for the purification of IL-18 binding protein (IL-18BP) from a fluid using aqueous two-phase partitioning.

## PROCESS FOR THE PURIFICATION OF IL-18 BINDING PROTEIN

### FIELD OF THE INVENTION

The present invention is in the field of protein purification. More specifically, it  
5 relates to a step for the purification of IL-18 binding protein (IL-18BP) from a fluid using aqueous two phase partitioning.

### BACKGROUND OF THE INVENTION

Proteins have become commercially important as drugs that are also generally  
10 called "biologics". One of the greatest challenges is the development of cost effective and efficient processes for purification of proteins on a commercial scale. While many methods are now available for large-scale preparation of proteins, crude products, such as body fluids or cell harvests, contain not only the desired product but also impurities, which are difficult to separate from the desired product. Moreover, biological sources of  
15 proteins usually contain complex mixtures of materials.

Biological sources such as cell culture conditioned media from cells expressing a desired protein product may contain less impurities, in particular if the cells are grown in serum-free medium. However, the health authorities request high standards of purity for proteins intended for human administration. In addition, many purification methods  
20 may contain steps requiring application of low or high pH, high salt concentrations or other extreme conditions that may jeopardize the biological activity of a given protein. Thus, for any protein it is a challenge to establish an efficient purification process allowing for sufficient purity while retaining the biological activity of the protein.

Protein purification generally comprises at least three phases or steps, namely a  
25 capture step, in which the desired protein is separated from other components present in the fluid such as DNA or RNA, ideally also resulting in a preliminary purification, an intermediate step, in which proteins are isolated from contaminants similar in size and/or physical/chemical properties, and finally a polishing step resulting in the high level of purity that is e.g. required from proteins intended for therapeutic administration  
30 in human or animals.

Typically, the protein purification steps are based on chromatographic separation of the compounds present in a given fluid. Widely applied chromatographic

methods are e.g. gel filtration, ion exchange chromatography, hydrophobic interaction chromatography, affinity chromatography or reverse-phase chromatography .

Aqueous Two-Phase Systems (A2PS) are an alternative to classical chromatographic processes. A2PS processes, have been used in the prior art for the 5 purification of proteins (see Table 1).

**Table 1: Proteins purified in A2PS**

Protein	Source	MW (kDa)	PI	Yield (%)	Purification factor	References
Xylanase	<i>Bacillus pumilus</i>	39	5.28	41	57	(Duarte et al., 2003)
β-glucosidase	<i>Aspergillus niger</i>	91	4.69	85	2	(Johansson & Reczey, 1998)
Lipase	<i>Acinetobacter calcoaceticus</i>	35	6.29	68	41	(Bompensieri et al., 1998)
Glucoamylase	-	52	4.68	96	3	(Minami & Kilikian, 1997)
BSA	Bovin	10	5.85	95	-	(Bleier et al., 2001)
Cutinase	<i>Saccharomyces cerevisiae</i>	24	6.82	95	5	(Costa et al., 2000)
GFP	<i>Escherishia coli</i>	27	5.67	91	3.3	(Li & Beitle, 2002)
Lysozyme	Chicken egg white	2	8.00	95	2.2	(Balasubramanian et al., 2003)

The purification of interferon-beta (IFN-β) from a production medium containing 10 a partially purified serum resulted in a 350-fold purified and up to 10-fold concentrated IFN-β sample with a specific activity of 3-7.10E10<sup>6</sup> IU/mg (Menge et al., 1987). However, the application of A2PS for the purification of therapeutic proteins in industrial scale is still limited.

A2PS is based on the partitioning of the target molecule between two immiscible 15 aqueous phases (for instance a PEG/salt system). This system is adapted for proteins extraction because the high water content of both phases (70-80 % w/w) means high biocompatibility and low interfacial tension minimizing degradation of the protein. The principle of protein purification by A2PS is e.g. exemplified for the purification of the insulin-like growth factor IGF-1 in US 5,695,958.

20 The choice of a suitable phase system (polymer/polymer; polymer/salt...) is the key step in a purification process based on A2PS. This system must show a high selective distribution of the target protein between the phases. Examples of couples

used for A2PS purification of proteins from various biological sources are illustrated in Table 2 .

The composition of aqueous polymer two-phase systems is usually represented in the rectangular form of a phase diagram, as illustrated in Fig. 5, taken from Hatti-Kaul, 2000. The vertical axis is commonly used for the component , which is enriched in the top phase. Amounts of polymer/salt X, polymer/salt Y and S of water are mixed. The total composition of one mixture is represented by one of the points A1, A2, or A3 on the phase diagram. The mixtures separate into two phases. The compositions of these two phases are represented by the points T and B, which are called nodes and are located at the binodal line. The binodal curve is the line separating two domains of compositions: one where the system is mono-phasic (left and bottom of the curve) and one where phase separation can be observed (top and right of the the curve). The line joining the points B and T representing the compositions of the coexisting phases is called a tie line. The points A1, A2, or A3, representing the total mixture must be positioned on the same tie line as the node B and T characterizing the compositions of the coexisting phases originated from these mixtures.

As shown in Fig. 5, mixtures of different total compositions represented by different points on the same tie line give rise to two-phase systems with identical compositions but different volumes of the coexisting phases. The volume ratio of the two phases can be approximated graphically by the ratio of the segment AB (top phase) and AT (bottom phase).

**Table 2: Examples of protein extraction based on A2PS**

Reference	Enzyme or protein	System used	Origin
(Menge et al., 1984) DE 2943026	Interferon	PEG-dextran	raw material
(Schütte et al., 1984)	D-Lactate dehydrogenase	PEG-phosphate	Lactobacillus cellubiosus
(Kim et al., 1985) US 4,508,825	Protease, amylase	PEG-dextran	Aspergillus orizae
(Schütte et al., 1985)	L-Leucin dehydrogenase	PEG-phosphate	Bacillus cereus
(Gustafsson et al., 1986) US 4,579,661	ADH, hexokinase	PEG-phosphate	Yeast

(Gustafsson et al., 1986)	Transferrin	PEG-phosphate	Blood plasma
(Paul et al., 1986) US 4,591,563	Dextran-sucrase	PEG-dextran	Leuconostoc mesenteroides
(van Wijnendaele et al., 1991) EP 0199698	Hepatitis B antigen	PEG-ammonium sulfate	Yeast
(van Wijnendaele et al., 1991) EP 0199698	Alpha-1-antitrypsin	PEG-ammonium sulfate	Yeast
(Dove & Mitra, 1988) US 4,684,723	Albumin, IgM, IgG, alpha-1-antitrypsin	PEG-phosphate	Blood plasma
(Tjemeld & Johansson, 1987) US 6,454,950	Lactate dehydrogenase	PEG-aquaphase PPT	Pig muscle
(Ananthapadmanabhan & Goddard, 1988) US 4,743,550	Alkaline protease	PEG-sodium sulfate	
(Brewer et al., 1988) US 4,728,613	Protease	PEG-sodium sulfate	whole fermentation bee
(Sieron et al., 1994) DD 288837	Recombinant proteins	PEG-polyvinylalcohol	
(Enfors et al., 1992) WO 92/97868	Human IgG	PEG-phosphate	Staphylococcus
(Guiliano & Szlag, 1992) US 5,093,254	Alcohol dehydrogenase (ADH)	PVP-maltodextrin	Baker's yeast
(Heinsohne et al., 1992) EP 0 477 284	Chymosin	PEG-sodium sulfate	Aspergillus niger var awamori
(Kirchberger et al., 1992) DD 298424	Alkalische phosphatase	PEG-dextran	Calf intestine
(Dos Reis Coimbra et al., 1994)	Beta-lactoglobulin	PEG-phosphate	Cheese whey
(Dos Reis Coimbra et al., 1994)	Alpha-lactoglobulin	PEG-phosphate	Cheese whey
(Cordes & Kula, 1994)	Formate dehydrogenase	PEG-phosphate	Candida boidinii
(Hart et al., 1994)	IGF	PEG-sodium sulfate	E.coli

(Lorch et al., 1994) US 5,328,841	EG	PEG-ammonium sulfate	Cellulase mixture
(Builder et al., 1995) US 5,407,819	IGF-I or mammalian polypeptide	PEG-citrate	E.coli
(Heinsohne & Hayenga, 1995) EP 0 477 284	Chymosin	PEG sodium sulfate	Bovine stomach
(Lee & Khan, 1995) US 5,407,579	Hemoglobin	PEG-phosphate	Bovine blood
(Braunstein et al., 1995) WO 96/23061	Different lipases and proteases	Detergents	Different organisms
(Guinn, 1997) US 5,907,035	Recombinant hemoglobin	PEG-magnesium sulfate	E.coli
(Hayenga et al., 1999) US 6,437,101	Human growth hormone	PEG-ammonium sulfate	E.coli
(Tjemeld et al., 2002) US 6,454,950	BSA	HM-EPO-water	Blood plasma
(Ageland et al., 2003) US 6,559,284	Apolipoprotein A and E	EO sub 30 PO-Reppal PES	E.coli

However, the mechanisms governing the partition of biological materials is still not well understood. It depends on many factors listed in Table 3 below. The most commonly used in current practice are concentration and molecular weight of phase-forming polymers, the type and quantity of the salt and the type and concentration of additives (usually inorganic salts). These factors are generally viewed as the most important to manipulate partitioning of protein to achieve better separation. Therefore, it is extremely difficult to find the appropriate A2PS system for a given protein to be purified from a given source, also because the protein intended for therapeutic use must remain fully functional both in terms of structure (e.g. no aggregation, truncations) and in terms of function.

**Table 3: Factors capable of steering solute partitioning in aqueous two-phase systems**

Type of phase-forming polymers <sup>a</sup>
Molecular weight of phase-forming polymers <sup>a</sup>
Concentrations of phase-forming polymers <sup>a</sup>
Type of additive <sup>b</sup>

Concentration of additive"  
Temperature  
pH  
Presence of complex-forming additives <sup>0</sup>  
Structural Modification <sup>d</sup>

<sup>a</sup>in aqueous single polymer-salt systems type and concentration of phase-forming salt is the factor equal to those of phase-forming polymer in two-polymer systems. <sup>b</sup>additives of low molecular weight, such as inorganic salts, urea, etc., with no specific affinity for the solute, "affinity ligands, such as drugs, triazine dyes, organic complexes, fatty acids, etc. "modification by chemical, enzymatic, etc. treatment resulting in elimination, incorporation, or alteration of topography of solvent-accessible moieties in the solute molecule.

Interleukin-18 binding protein (IL-18BP) is a naturally occurring soluble protein that was initially affinity purified, on an IL-18 column, from urine (Novick et al. 1999). IL-10 18BP abolishes IL-18 induction of IFN- $\gamma$  and IL-18 activation of NF- $\kappa$ B *in vitro*. In addition, IL-18BP inhibits induction of IFN- $\gamma$  in mice injected with LPS.

The IL-18BP gene was localized to the human chromosome 11, and no exon coding for a transmembrane domain could be found in the 8.3 kb genomic sequence comprising the IL-18BP gene. Four isoforms of IL-18BP generated by alternative mRNA splicing have been identified in humans so far. They were designated IL-18BP a, b, c, and d, all sharing the same N-terminus and differing in the C-terminus (Novick et al 1999). These isoforms vary in their ability to bind IL-18 (Kim et al. 2000). Of the four human IL-18BP (hIL-18BP) isoforms, isoforms a and c are known to have a neutralizing capacity for IL-18. The most abundant IL-18BP isoform, isoform a, exhibits a high affinity for IL-18 with a rapid on-rate and a slow off-rate, and a dissociation constant (Kd) of approximately 0.4 nM (Kim et al. 2000). IL-18BP is constitutively expressed in the spleen, and belongs to the immunoglobulin superfamily. The residues involved in the interaction of IL-18 with IL-18BP have been described through the use of computer modelling (Kim et al. 2000) and based on the interaction between the similar protein IL-1 $\beta$  with the IL-1 R type I (Vigers et al. 1997).

IL-18BP is constitutively present in many cells (Puren et al. 1999) and circulates in healthy humans (Urushihara et al. 2000), representing a unique phenomenon in cytokine biology. Due to the high affinity of IL-18BP to IL-18 (Kd = 0.4 nM) as well as the high concentration of IL-18BP found in the circulation (20 fold molar excess over IL-30 18), it has been speculated that most, if not all of the IL-18 molecules in the circulation are bound to IL-18BP. Thus, the circulating IL-18BP that competes with cell surface

receptors for IL-18 may act as a natural anti-inflammatory and an immunosuppressive molecule.

IL-18BP has been suggested as a therapeutic protein in a number of diseases and disorders, such as psoriasis, Crohn's Disease, rheumatoid arthritis, psoriatic arthritis, liver injury, sepsis, atherosclerosis, ischemic heart diseases, allergies, etc., see 5 e.g. WO9909063, WO0107480, WO0162285, WO0185201, WO02060479, WO02096456, WO03080104, WO02092008, WO02101049, WO03013577.

The prior art does not describe a purification process of IL-18BP.

10

#### SUMMARY OF THE INVENTION

The present invention is based on the development of an efficient purification step for IL-18 binding protein (IL-18BP) that is based on aqueous-two phase partitioning.

15

Therefore, in a first aspect, the invention relates to a process for the purification of IL-18 binding protein (IL-18BP) from a fluid comprising at least one step comprising an aqueous two-phase system.

A second aspect of the invention relates to the use of an aqueous two-phase system for the purification of IL-18BP from a fluid.

20

A third aspect of the invention relates to purified IL-18BP obtained by a process according to the invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the results from Capillary Zone Electrophoresis (CZE) profiles of leads 25 identified from the statistical model.

Fig. 2 shows the Tie-line for conditions Val2-1.

Fig. 3 shows the Tie-line for conditions Val2-2.

Fig. 4 shows the Tie-line for conditions Val2-5.

Fig. 5 illustrates the principle of establishing a tie-line in an aqueous two-phase system 30 (taken from Hatti-Kaul, 2000).

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the development of a step for the purification process of IL-18BP.

The invention relates to a process for purifying IL-18BP from a fluid comprising 5 at least one step using aqueous two-phase partitioning. Such an aqueous two-phase system may be used as a single step of purification of IL-18BP. It may also be used as one step among other steps based on other purification methods. It may further be used in multiple steps of the purification process, i.e. two, three or more steps are based on aqueous two phase partitioning. Should the purification process comprise 10 more than one step based on aqueous two-phase system, the individual aqueous two-phase system used may be the same system, or based on different systems, e.g. different polymers, salts, or the like.

In accordance with the present invention, the aqueous two-phase system may be any suitable phase system of two immiscible phases such as e.g. polymer/polymer 15 or polymer/salt phases, as long as the system provides a highly selective distribution of the target protein between the phases.

The polymer can be e.g. dextran, polyvinylalcohol, or maltodextrin. Preferably, the aqueous two-phase system comprises a polyethylene glycol (PEG) phase and a salt phase.

20 The PEG to be used in accordance with the purification process of the invention may have any suitable molecular weight. In a preferred embodiment, the PEG has a molecular weight ranging between about 2'000 and about 12'000, it may be about 3000, or about 4000, or about 5000, or about 6000, or about 7000, or about 8000, or about 9000, or about 10000, or about 11000. It is more preferred that the PEG has a 25 molecular weight of about 10'000.

Suitable salts that may be used in the process of the present invention comprise phosphate salts or sulfate salts. The salt phase may e.g. comprise  $\text{KH}_2\text{PO}_4$ . Preferably, the salt phase comprises  $(\text{NH}_4)\text{SO}_4$ . Alternatively, the salt phase comprises  $(\text{Na}_2)\text{SO}_4$ .

30 The concentrations of the polymer in the polymer phase may vary. In a preferred embodiment, the initial concentration of the polymer, preferably PEG, is less than about 35% [w/w], less than about 30% [w/w], 29% [w/w], 28% [w/w], 27% [w/w], 26% [w/w], 25% [w/w], 24% [w/w], 23% [w/w], 22% [w/w], 21% [w/w], 20% [w/w], 19% [w/w], 18% [w/w], 17% [w/w], 16% [w/w], 15% [w/w], 14% [w/w], 13% [w/w], 12% [w/w],

11% [w/w], 10% [w/w], 9% [w/w], 8% [w/w], 7% [w/w], 6% [w/w], 5% [w/w], 4% [w/w], 3% [w/w], 2% [w/w], or 1% [w/w].

The concentration of the salt in the salt phase may also vary, in particular depending on the concentration used for the polymer phase. In a preferred embodiment,  $\text{Na}_2\text{SO}_4$  is used at a concentration of less than about 30 % [w/w], 25% [w/w], 20% [w/w], 16% [w/w], 15% [w/w], 14% [w/w], 13 % [w/w], 12% [w/w], 11% [w/w], 10% [w/w], 9% [w/w], 8% [w/w], 7% [w/w], 6% [w/w], 5% [w/w], 4% [w/w], 3% [w/w], 2% [w/w] or 1% [w/w].

In a highly preferred embodiment of the invention, the concentrations of the two phases are calculated according to the following formula:

$$y = -2.5108x + 35.159$$

wherein y = PEG in % [w/w] and x =  $(\text{Na}_2\text{SO}_4)$  in % [w/w].

In a further highly preferred embodiment, the concentrations of the two phases are calculated according to the following formula:

$$y = -2.5573X + 35.757$$

wherein y = PEG in % [w/w] and x =  $(\text{Na}_2\text{SO}_4)$  in % [w/w].

In yet a further highly preferred embodiment, the concentrations of the two phases are calculated according to the following formula:

$$y = -2.1182x + 35.355$$

wherein y = PEG in % [w/w] and x =  $(\text{Na}_2\text{SO}_4)$  in % [w/w].

In accordance with the present invention, the process is carried out at a pH ranging between pH 4 and 9, it may be carried out at about pH 4, pH 5, pH 6, pH 7, pH 8, or pH 9. Preferably, it is carried out at about pH 5 or at about pH 7.

The process according to the invention may be carried out at any suitable temperature, e.g. at 4 °C, 6.5 °C, 13 °C, 19.5 °C, 30 °C, but preferably the process is carried out at room temperature.

In a preferred embodiment, the step using an aqueous two-phase system of the invention is a capture step, i.e. an initial step of a purification procedure comprising one or more further steps.

The purification step of the invention may remove >10%, >20%, >30%, >40%, >50% or >60% or even >70% of the total contaminants present in the crude material. The yield obtainable with the purification step of the invention may be >50%, >60%, >70% or >80% or even >90%.

In a further preferred embodiment, the process of the invention further comprises one or more additional purification steps.

Preferably, the additional purification steps are selected from metal ion affinity chromatography, ion exchange chromatography, hydrophobic interaction chromatography, and reverse phase chromatography.

Hydrophobic charge-induction chromatography is preferably carried out on a resin having 4-mercaptopethyl-pyridine (MEP) as immobilized ligand. MEP-Hypercel® is a resin that is particularly suitable in the frame of the present invention.

The ion exchange chromatography step is preferably carried out using a carboxymethyl (CM)-resin.

The affinity chromatography step is preferably immobilized metal ion affinity chromatography, and chelating sepharose is an example for a resin that may be used to carry out this chromatographic step.

Hydrophobic interaction chromatography (HIC) may be carried out on any known HIC resin, such as a resin having alkyl- or aryl-residues as immobilized ligand. Butyl-, octyl- or phenyl-sepharose (agarose) are examples of such HIC resins.

A preferred material useful for the reverse phase step is reverse-phase-source 30 RPC.

In a highly preferred embodiment, the purification step of the invention is followed by the steps of:

- a) Subjecting the fluid to immobilized metal ion affinity chromatography;
- b) Subjecting the eluate of the metal ion affinity chromatography to hydrophobic charge-interaction chromatography;
- c) Subjecting the eluate of the hydrophobic charge-interaction chromatography to ion exchange chromatography;
- d) Subjecting the flow-through of the ion exchange chromatography to hydrophobic interaction chromatography;
- e) Subjecting the eluate of the hydrophobic interaction chromatography to reverse phase chromatography.

The fluid is preferably subjected to ultrafiltration or dafiltration prior to step (a).

While the order of the above steps (a) to (e) is preferred, the steps of the process of the invention may be carried out in any order that leads to a purified protein product.

Step (a) is preferably carried out on a chelating sepharose column, such as a chelating sepharose fast flow column, having  $Zn^{2+}$  ions chelated. Preferably, binding of IL-18BP is carried out at pH  $8.5 \pm 0.1$ , preferably in 50 mM sodium phosphate and 0.5 M NaCl having this pH. Elution is preferably carried out at pH  $9.0 \pm 0.1$ , e.g. in 0.075 M ammonium acetate having this pH.

Step (b) is preferably carried out on a MEP (4-mercaptopethylpyridine derivative) column, such as MEP HyperCel® (LifeSciences). Binding of IL-18BP is carried out preferably at pH  $6.1 \pm 0.1$ , e.g. in PBS 1X + 1 NaCl having this pH. Elution is carried out preferably at pH  $8.4 \pm 0.1$ , e.g. in with 20 mM phosphate buffer plus 35% propylene glycol, the mixture having pH  $8.4 \pm 0.1$ .

Step (c) is preferably carried out on a carboxymethyl-sepharose (CM) column. This is a step in which the flow-through is collected for further purification. This step is based on the fact that in specific circumstances relating e.g. to salt and pH conditions, IL-18BP does not bind to the resin, while impurities bind to it. Preferably, step (c) is carried out at pH  $6.0+0.2$ , for example in the presence of 1 mM MES (N-morpholinoethanesulfonic acid).

Step (d) is preferably carried out on a phenyl sepharose column, such as a Phenyl-Sepahrose Fast Flow column. Preferably, binding of IL-18BP is carried out at about pH  $9.1 \pm 0.2$ , e.g. in 50 mM sodium borate and 0.9M ammonium sulphate having this pH. The elution from the phenyl-sepharose column is preferably carried out at pH  $9.1 \pm 0.2$  in the presence of an elevated salt concentration, such as in 50 mM sodium borate  $9.1 \pm 0.2$ , 0.15 M ammonium sulphate having this pH.

Step (e) is preferably carried out on a Source 30 RPC column. Binding of IL-18BP to the column material is preferably carried out at pH  $9.1 \pm 0.2$ , e.g. in 50 mM sodium borate buffer. Elution is preferably carried out using a gradient, IL-18BP eluting around 28-32% of 0,1 % trifluoroacetic acid (TFA) in acetonitrile.

It is understood that the conditions described above in connection with steps (a) to (e) of the purification may also be applied when carrying out single steps of the invention, or (sub-)combinations of steps.

In a further preferred embodiment of the present purification process, one or more ultrafiltration steps are performed. Ultrafiltration is e.g. useful for the concentration of the target protein, for buffer exchange, or for the removal of small molecular weight components in the eluates resulting from previous chromatographic steps. This

ultrafiltration allows to remove organic solvent, TFA and salts from the previous step, to equilibrate the IL-18BP in the bulk buffer and to concentrate the molecule to the desired concentration. Such ultrafiltration may e.g. be performed on ultrafiltration media excluding components having molecular weights below 5 kDa.

5 Preferably, ultrafiltration is carried out between steps (b) and (c), and/or after step (e). More preferably, two ultrafiltration steps are carried out, one between steps (b) and (c) and one after step (e).

In order to facilitate storage or transport, for instance, the material may be frozen and thawed before and/or after any purification step of the invention.

10

If the protein purified according to the process of the invention is intended for administration to humans, it is advantageous to further include steps of virus removal. Preferably, a virus removal filtration step is carried out between steps (d) and (e). It is further preferred that a virus removal filtration step is carried out after step (e). More 15 preferably, the process comprises two virus removal steps one of which is carried out between steps (d) and (e), the other of which is carried out after step (e).

The fluid from which IL-18BP is purified in accordance with the present invention is preferably selected from cell culture harvest, cell lysate, cell extract, tissue extract, blood plasma, serum, milk, urine, ascites, plant extract, or a fraction derived from an 20 earlier protein purification step.

The fluid may be unclarified crude cell culture harvest or clarified crude cell culture harvest, and it is preferably derived from Chinese Hamster Ovary (CHO) cells. Clarified crude cell culture harvest refers to a cell culture conditioned medium from which cells and debris has been removed, e.g. by centrifugation or filtration techniques. 25 If unclarified crude cell culture harvest is used as the starting material for the process of the invention, cells and debris are present. As shown in the example below, the purification step of the invention is capable of capturing IL-18BP even from unclarified cell culture harvest that has not been pre-treated.

The CHO cells producing IL-18BP may be grown in suspension, or attached to a 30 surface of a carrier such as e.g. a microcarrier. Preferably, the cells are grown in suspension.

In accordance with the present invention, IL-18BP to be purified may be native, i.e. naturally occurring IL-18BP. It may thus be purified from any natural source or material, such as e.g. from body fluids such as urine.

IL-18BP may also be derived from any animal or human source. Preferably, the 5 IL-18BP to be purified is human, and more preferably it is recombinant IL-18BP. Recombinant IL-18BP may be produced in prokaryotic expression systems, such as in bacterial systems as *Escherichia coli*. It may also be produced in eukaryotic expression systems, such as yeast, insect, or mammalian cells. In accordance with the present invention, it is preferred to express IL-18BP in mammalian cells such as animal cell 10 lines, or in human cell lines. Chinese hamster ovary cells (CHO) are an example of a cell line that is particularly suitable for expression of IL-18BP.

Since IL-18BP is a soluble, secreted protein, it is released into the cell culture supernatant, either by means of its natural signal peptide, or by means of a heterologous signal peptide, i.e. a signal peptide derived from another secreted protein 15 which may be more efficient in the particular expression system used. The fluid from which IL-18BP is purified is thus preferably cell culture supernatant, such as e.g. CHO-cell supernatant. It is more preferred to purify the protein from the supernatant of cells that were grown in serum-free medium, i.e. in culturing medium not containing serum derived from fetal calf or other animal sources.

20 The term "IL-18 binding protein" is used herein synonymously with "IL-18BP". This term relates IL-18 binding proteins such as the ones defined in WO 99/09063 or in Novick et al., 1999. The term IL-18BP includes splice variants and/or isoforms of IL-18 binding proteins, as the ones defined in Kim et al., 2000, in particular human isoforms a and c of IL-18BP. The term "IL-18PB", as used herein, further includes muteins, 25 functional derivatives, active fractions, fused proteins, circularly permuted proteins and slats of IL-18BP as defined in WO 99/09063.

The IL-18BP subject to the purification process according to the present invention may be glycosylated or non-glycosylated, it may be derived from natural sources, such as urine, or it may preferably be produced recombinantly. Recombinant 30 expression may be carried out in prokaryotic expression systems like *E. coli*, or in eukaryotic, and preferably in mammalian, expression systems.

As used herein the term "muteins" refers to analogs of an IL-18BP, or analogs of a viral IL-18BP, in which one or more of the amino acid residues of a natural IL-18BP

or viral IL-18BP are replaced by different amino acid residues, or are deleted, or one or more amino acid residues are added to the natural sequence of an IL-18BP, or a viral IL-18BP, without changing considerably the activity of the resulting products as compared with the wild type IL-18BP or viral IL-18BP. These muteins are prepared by

5 known synthesis and/or by site-directed mutagenesis techniques, or any other known technique suitable therefor.

Muteins in accordance with the present invention include proteins encoded by a nucleic acid, such as DNA or RNA, which hybridizes to DNA or RNA, which encodes an IL-18BP or encodes a viral IL-18BP (WO9909063) under stringent conditions. The term

10 "stringent conditions" refers to hybridization and subsequent washing conditions, which those of ordinary skill in the art conventionally refer to as "stringent". See Ausubel et al., Current Protocols in Molecular Biology, *supra*, Interscience, N.Y., §§6.3 and 6.4 (1987, 1992). Without limitation, examples of stringent conditions include washing conditions 12-20°C below the calculated Tm of the hybrid under study in, e.g., 2 x SSC and 0.5%

15 SDS for 5 minutes, 2 x SSC and 0.1% SDS for 15 minutes; 0.1 x SSC and 0.5% SDS at 37°C for 30-60 minutes and then, a 0.1 x SSC and 0.5% SDS at 68°C for 30-60 minutes. Those of ordinary skill in this art understand that stringency conditions also depend on the length of the DNA sequences, oligonucleotide probes (such as 10-40 bases) or mixed oligonucleotide probes. If mixed probes are used, it is preferable to

20 use tetramethyl ammonium chloride (TMAC) instead of SSC. See Ausubel, *supra*.

Identity reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotides or two polypeptide sequences, respectively,

25 over the length of the sequences being compared.

For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be

30 determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

Methods for comparing the identity and homology of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al., 1984), for example the programs BESTFIT and GAP, may be used to determine the % identity between two 5 polynucleotides and the % identity and the % homology between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (1981) and finds the best single region of similarity between two sequences. Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, 1990, Altschul 10 S F et al, 1997, accessible through the home page of the NCBI at [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)) and FASTA (Pearson W R, 1990).

Any such mutein preferably has a sequence of amino acids sufficiently duplicative of that of an IL-18BP, or sufficiently duplicative of a viral IL-18BP, such as to have substantially similar activity to IL-18BP. One activity of IL-18BP is its capability of 15 binding IL-18. As long as the mutein has substantial binding activity to IL-18, it can be used in the purification of IL-18, such as by means of affinity chromatography, and thus can be considered to have substantially similar activity to IL-18BP. Thus, it can be determined whether any given mutein has substantially the same activity as IL-18BP by means of routine experimentation comprising subjecting such a mutein, e.g., to a 20 simple sandwich competition assay to determine whether or not it binds to an appropriately labeled IL-18, such as radioimmunoassay or ELISA assay.

In a preferred embodiment, any such mutein has at least 40% identity or homology with the sequence of either an IL-18BP or a virally-encoded IL-18BP homologue, as defined in WO 99/09063. More preferably, it has at least 50%, at least 25 60%, at least 70%, at least 80% or, most preferably, at least 90% identity or homology thereto.

Muteins of IL-18BP polypeptides or muteins of viral IL-18BPs, which can be used in accordance with the present invention, or nucleic acid coding therefor, include a finite set of substantially corresponding sequences as substitution peptides or 30 polynucleotides which can be routinely obtained by one of ordinary skill in the art, without undue experimentation, based on the teachings and guidance presented herein.

Preferred changes for muteins in accordance with the present invention are what are known as "conservative" substitutions. Conservative amino acid substitutions of IL-18BP polypeptides or proteins or viral IL-18BPs, may include synonymous amino acids within a group which have sufficiently similar physicochemical properties that 5 substitution between members of the group will preserve the biological function of the molecule (Grantham, 1974). It is clear that insertions and deletions of amino acids may also be made in the above-defined sequences without altering their function, particularly if the insertions or deletions only involve a few amino acids, e.g., under thirty, and preferably under ten, and do not remove or displace amino acids which are 10 critical to a functional conformation, e.g., cysteine residues. Proteins and muteins produced by such deletions and/or insertions come within the purview of the present invention.

Preferably, the synonymous amino acid groups are those defined in Table 4. More preferably, the synonymous amino acid groups are those defined in Table 5; and 15 most preferably the synonymous amino acid groups are those defined in Table 6.

TABLE 4

## Preferred Groups of Synonymous Amino Acids

	Amino Acid	Synonymous Group
20	Ser	Ser, Thr, Gly, Asn
	Arg	Arg, Gln, Lys, Glu, His
	Leu	Ile, Phe, Tyr, Met, Val, Leu
	Pro	Gly, Ala, Thr, Pro
	Thr	Pro, Ser, Ala, Gly, His, Gln, Thr
25	Ala	Gly, Thr, Pro, Ala
	Val	Met, Tyr, Phe, He, Leu, Val
	Gly	Ala, Thr, Pro, Ser, Gly
	ile	Met, Tyr, Phe, Val, Leu, Ile
	Phe	Trp, Met, Tyr, Ile, Val, Leu, Phe
30	Tyr	Trp, Met, Phe, He, Val, Leu, Tyr
	Cys	Ser, Thr, Cys
	His	Glu, Lys, Gln, Thr, Arg, His
	Gln	Glu, Lys, Asn, His, Thr, Arg, Gln
	Asn	Gln, Asp, Ser, Asn
35	Lys	Glu, Gln, His, Arg, Lys
	Asp	Glu, Asn, Asp
	Glu	Asp, Lys, Asn, Gln, His, Arg, Glu
	Met	Phe, He, Val, Leu, Met
	Trp	Trp

40

TABLE 5

## More Preferred Groups of Synonymous Amino Acids

	Amino Acid	Synonymous Group
5	Ser	Ser
	Arg	His, Lys, Arg
	Leu	Leu, Ile, Phe, Met
	Pro	Ala, Pro
	Thr	Thr
	Ala	Pro, Ala
	Val	Val, Met, Ile
	Gly	Gly
10	Le	Le, Met, Phe, Val, Leu
	Phe	Met, Tyr, Ile, Leu, Phe
	Tyr	Phe, Tyr
	Cys	Cys, Ser
	His	His, Gln, Arg
	Gln	Glu, Gln, His
15	Asn	Asp, Asn
	Lys	Lys, Arg
	Asp	Asp, Asn
	Glu	Glu, Gln
	Met	Met, Phe, Ile, Val, Leu
20	Trp	Trp

TABLE 6

## Most Preferred Groups of Synonymous Amino Acids

	Amino Acid	Synonymous Group
25	Ser	Ser
	Arg	Arg
	Leu	Leu, Ile, Met
	Pro	Pro
	Thr	Thr
	Ala	Ala
	Val	Val
	Gly	Gly
30	Ile	Le, Met, Leu
	Phe	Phe
	Tyr	Tyr
	Cys	Cys, Ser
	His	His
	Gln	Gln
35	Asn	Asn
	Lys	Lys
	Asp	Asp
	Glu	Glu
	Met	Met, Ile, Leu
40	Trp	Met
45		

Examples of production of amino acid substitutions in proteins which can be used for obtaining muteins of IL-18BP polypeptides or proteins, or muteins of viral IL-18BPs, for use in the present invention include any known method steps, such as 50 presented in US patents 4,959,314, 4,588,585 and 4,737,462, to Mark et al; 5,116,943

to Koths et al., 4,965,195 to Namen et al; 4,879,111 to Chong et al; and 5,017,691 to Lee et al; and lysine substituted proteins presented in US patent No. 4,904,584 (Shaw et al).

The term "fused protein" refers to a polypeptide comprising an IL-18BP, or a 5 viral IL-18BP, or a mutein or fragment thereof, fused with another protein, which, e.g., has an extended residence time in body fluids. An IL-18BP or a viral IL-18BP, may thus be fused to another protein, polypeptide or the like, e.g., an immunoglobulin or a fragment thereof.

"Functional derivatives" as used herein cover derivatives of IL-18BPs or a viral 10 IL-18BP, and their muteins and fused proteins, which may be prepared from the functional groups which occur as side chains on the residues or the N- or C-terminal groups, by means known in the art, and are included in the invention as long as they remain pharmaceutically acceptable, i.e. they do not destroy the activity of the protein which is substantially similar to the activity of IL-18BP, or viral IL-18BPs, and do not 15 confer toxic properties on compositions containing it.

These derivatives may, for example, include polyethylene glycol side-chains, which may mask antigenic sites and extend the residence of an IL-18BP or a viral IL-18BP in body fluids. Other derivatives include aliphatic esters of the carboxyl groups, amides of the carboxyl groups by reaction with ammonia or with primary or secondary 20 amines, N-acyl derivatives of free amino groups of the amino acid residues formed with acyl moieties (e.g. alkanoyl or carbocyclic aroyl groups) or O-acyl derivatives of free hydroxyl groups (for example that of seryl or threonyl residues) formed with acyl moieties.

As "active fractions" of an IL-18BP, or a viral IL-18BP, muteins and fused 25 proteins, the present invention covers any fragment or precursors of the polypeptide chain of the protein molecule alone or together with associated molecules or residues linked thereto, e.g., sugar or phosphate residues, or aggregates of the protein molecule or the sugar residues by themselves, provided said fraction has substantially similar activity to IL-18BP.

30 The term "salts" herein refers to both salts of carboxyl groups and to acid addition salts of amino groups of IL-18 inhibitor molecule, or analogs thereof. Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts

with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like. Acid addition salts include, for example, salts with mineral acids, such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids, such as, for example, acetic acid or oxalic acid. Of course, any such salts must retain the biological activity of the IL-18 inhibitor, such as induction of IFN-gamma in blood cells.

The sequences of IL-18BP and its splice variants/isoforms can be taken from WO99/09063 or from Novick et al., 1999, as well as from Kim et al., 2000.

Functional derivatives of IL-18BP may be conjugated to polymers in order to improve the properties of the protein, such as the stability, half-life, bioavailability, tolerance by the human body, or immunogenicity. To achieve this goal, IL18-BP may be linked e.g. to Polyethyenglycol (PEG). PEGylation may be carried out by known methods, described in WO 92/13095, for example.

Therefore, in a preferred embodiment, the functional derivative comprises at least one moiety attached to one or more functional groups, which occur as one or more side chains on the amino acid residues. An embodiment in which the moiety is a polyethylene glycol (PEG) moiety is highly preferred.

In a further preferred embodiment of the invention, IL-18BP comprises an immunoglobulin fusion, i.e. the inhibitor of IL-18 is a fused protein comprising all or part of an IL-18 binding protein, which is fused to all or a portion of an immunoglobulin. Methods for making immunoglobulin fusion proteins are well known in the art, such as the ones described in WO 01/03737, for example. The person skilled in the art will understand that the resulting fusion protein of the invention retains the biological activity of IL-18BP, in particular the binding to IL-18. The fusion may be direct, or via a short linker peptide which can be as short as 1 to 3 amino acid residues in length or longer, for example, 13 amino acid residues in length. Said linker may be a tripeptide of the sequence E-F-M (Glu-Phe-Met), for example, or a 13-amino acid linker sequence comprising Glu-Phe-Gly-Ala-Gly-Leu-Val-Leu-Gly-Gln-Phe-Met introduced between the IL-18BP sequence and the immunoglobulin sequence. The resulting fusion protein has improved properties, such as an extended residence time in body fluids (half-life), increased specific activity, increased expression level, or the purification of the fusion protein is facilitated.

In a preferred embodiment, IL-18BP is fused to the constant region of an Ig molecule. Preferably, it is fused to heavy chain regions, like the CH2 and CH3 domains of human IgG1, for example. The generation of specific fusion proteins comprising IL-18BP and a portion of an immunoglobulin are described in example 11 of WO 5 99/09063, for example. Other isoforms of Ig molecules are also suitable for the generation of fusion proteins according to the present invention, such as isoforms IgG<sub>2</sub> or IgG<sub>4</sub>, or other Ig classes, like IgM or IgA, for example. Fusion proteins may be monomeric or multimeric, hetero- or homomultimeric.

10 In a third aspect, the invention relates to a protein preparation resulting from the process of purification according to the invention. Such protein preparation preferably contains IL-18BP in a purity that is >50%, more preferably >60%, and most preferably >70. The IL-18BP present in this protein preparation has preferably a low content of dimers and aggregates, preferably no dimers and aggregates at all. It is further 15 preferred that the extent of truncation of IL-18BP present in the protein preparation of the invention is <10%, it may be <9%, <8%, <7%, <6%, and preferably <5%, or even <4%, <3%, <2%, or <1%.

The IL-18BP that has been purified in accordance with the present invention further preferably has a specific isoform profile, as measured e.g. by capillary zone 20 electrophoresis. It is preferred that the IL-18BP contains less than 5% of basic isoforms, less than 25% of less acidic isoforms, more than 45% of acidic isoforms, and more than 15% of highly acidic isoforms. Isoform classification is as defined in the Example below.

Should further purification steps be used, preferably using the further steps 25 described above, the IL-18BP preparation obtained may contain less than 20 % of impurities, preferably less than about 15%, or about 14%, or about 13%, or about 12%, or about 11% of impurities. Preferably, it contains less than about 10%, or about 5%, 3%, 2% or 1% of impurities, or it may be purified to homogeneity, i.e. essentially being free from proteinaceous contaminants.

30 Purified IL-18BP may be intended for therapeutic use, i.e. for administration to patients. If purified IL-18BP is administered to patients, it is preferably administered systemically, and preferably subcutaneously or intramuscularly, or topically, i.e. locally.

Rectal or intrathecal administration may also be suitable, depending on the specific use of purified IL-18BP.

For this purpose, purified IL-18BP may be formulated as a pharmaceutical composition, i.e. together with a pharmaceutically acceptable carrier, excipients or the like.

The definition of "pharmaceutically acceptable" is meant to encompass any carrier, which does not interfere with effectiveness of the biological activity of the active ingredient and that is not toxic to the host to which it is administered. For example, for parenteral administration, the active protein(s) may be formulated in a unit dosage form for injection in vehicles such as saline, dextrose solution, serum albumin and Ringer's solution.

The active ingredients of the pharmaceutical composition according to the invention can be administered to an individual in a variety of ways. The routes of administration include intradermal, transdermal (e.g. in slow release formulations), intramuscular, intraperitoneal, intravenous, subcutaneous, oral, intracranial, epidural, topical, rectal, and intranasal routes. Any other therapeutically efficacious route of administration can be used, for example absorption through epithelial or endothelial tissues or by gene therapy wherein a DNA molecule encoding the active agent is administered to the patient (e.g. via a vector) which causes the active agent to be expressed and secreted in vivo. In addition, the protein(s) according to the invention can be administered together with other components of biologically active agents such as pharmaceutically acceptable surfactants, excipients, carriers, diluents and vehicles.

For parenteral (e.g. intravenous, subcutaneous, intramuscular) administration, the active protein(s) can be formulated as a solution, suspension, emulsion or lyophilized powder in association with a pharmaceutically acceptable parenteral vehicle (e.g. water, saline, dextrose solution) and additives that maintain isotonicity (e.g. mannitol) or chemical stability (e.g. preservatives and buffers). The formulation is sterilized by commonly used techniques.

The bioavailability of the active protein(s) according to the invention can also be ameliorated by using conjugation procedures which increase the half-life of the molecule in the human body, for example linking the molecule to polyethyleneglycol (PEG), as described in the PCT Patent Application WO 92/13095.

The therapeutically effective amounts of the active protein(s) will be a function of many variables, including the type of antagonist, the affinity of the antagonist for IL-18, any residual cytotoxic activity exhibited by the antagonists, the route of administration, the clinical condition of the patient (including the desirability of maintaining a non-toxic level of endogenous IL-18 activity).

A "therapeutically effective amount" is such that when administered, the IL-18 inhibitor results in inhibition of the biological activity of IL-18. The dosage administered, as single or multiple doses, to an individual will vary depending upon a variety of factors, including IL-18 inhibitor pharmacokinetic properties, the route of administration, patient conditions and characteristics (sex, age, body weight, health, size), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired. Adjustment and manipulation of established dosage ranges are well within the ability of those skilled in the art, as well as in vitro and in vivo methods of determining the inhibition of IL-18 in an individual.

Purified IL-18BP may be used in an amount of about 0.001 to 100 mg/kg or about 0.01 to 10 mg/kg or body weight, or about 0.1 to 5 mg/kg of body weight or about 1 to 3 mg/kg of body weight or about 2 mg/kg of body weight.

In further preferred embodiments, the purified IL-18BP is administered daily or every other day or three times per week or once per week.

The daily doses are usually given in divided doses or in sustained release form effective to obtain the desired results. Second or subsequent administrations can be performed at a dosage which is the same, less than or greater than the initial or previous dose administered to the individual. A second or subsequent administration can be administered during or prior to onset of the disease.

According to the invention, purified IL-18BP can be administered prophylactically or therapeutically to an individual prior to, simultaneously or sequentially with other therapeutic regimens or agents (e.g. multiple drug regimens), in a therapeutically effective amount.

Purified IL-18BP may be used for preparation of a medicament for treatment and/or prevention of a number of diseases or disorders. Such diseases or disorders are preferably IL-18 mediated disorders. In particular, purified IL-18BP may be used for treatment and/or prevention of psoriasis, psoriatic arthritis, Crohn's Disease, inflammatory bowel disease, rheumatoid arthritis, liver injury such as alcoholic liver

cirrhosis, sepsis, atherosclerosis, ischemic heart diseases, allergies, in particular delayed-type hypersensitivity, and closed head injury.

In a third aspect, the invention relates to the use of an aqueous two-phase system for the purification IL-18 binding protein (IL-18BP). Preferably, the aqueous two-phase system is used for the capture of IL-18BP from a fluid.

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations and conditions without departing from the spirit and scope of the invention and without undue experimentation.

While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

All references cited herein, including journal articles or abstracts, published or unpublished U.S. or foreign patent application, issued U.S. or foreign patents or any other references, are entirely incorporated by reference herein, including all data, tables, figures and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.

Reference to known method steps, conventional methods steps, known methods or conventional methods is not any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various application such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be

understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

5

EXAMPLE:

**Purification of recombinant, human IL-18BP from serum-free CHO cell harvest**

10 In the present example, a purification step based on an aqueous two-phase system for the purification of IL-18PB from a CHO cell harvest has been developed. To this end, the following steps were carried out:

1. Selection of the phase-forming components (couples) to be screened
2. First factorial design experiments. For every single selected couple, all major
- 15 factors affecting the protein partitioning were screened over a broad experimental space
3. Second factorial design experiments. Only important factors affecting the partitioning of the target protein were screened over a reduced experimental space
4. Leads predicted by the model were experimentally verified.
5. Leads were optimized and fine tuned.
- 20 6. Leads were scaled-up to 1-liter scale.

Selection of the two-phase forming components

25 Different factors were considered for the selection of the phase forming components: (i) process compatibility; (ii) components price; (iii) components availability; (iv) literature data. In terms of process compatibility, price and availability, the couples PEG/salt were appropriate. The PEGZ(NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, PEG/KH<sub>2</sub>PO<sub>4</sub> and PEG/Na<sub>2</sub>SO<sub>4</sub> were selected.

30 Therefore the three couples studied were:

1. PEGZ(NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>
2. PEGZKH<sub>2</sub>PO<sub>4</sub>
3. PEGZNa<sub>2</sub>SO<sub>4</sub>

First cycle of factorial design experiments

The aim of this cycle of factorial design experiments was to select the appropriate phase forming components showing extreme protein partitioning.

5 The experiment used was a central composite design including a  $2^{5+1}$  fractional factorial, 10 star points and 2 centre points. The design enabled estimation of all main effects and two-factor interactions and all pure quadratic effects of the experimental factors. Table A summarizes the type of experimental factors and levels considered. It corresponds to 28 experiments per couple selected.

10

**Table A: Factors screened in the first cycle of factorial design experiments**

Factor	Level				
Temperature °C	4	6.5	13	19.5	30
pH <sup>a</sup>	5	6	7	8	9
NaCl cone % (w/w)	0	2	4	6	8
PEG Mw	2000		6000		10000
Tie-line length <sup>a</sup>	-1		0		1

<sup>a</sup> Tie-line length is related to phase forming components concentration.

The experimental conditions that were used are described in Tables B, C and D.

15

**Table B: Conditions for IL-18BP in PEG/KH<sub>2</sub>PO<sub>4</sub>**

Run Order	NaCl% [w/w]	PH	PEG Mw	Tie-line	KH <sub>2</sub> PO <sub>4</sub> % [w/w]	PEG% [w/w]	Temp [°C]
7	0.5	6	2000	-1	10	12	19.5
16	1.5	6	2000	-1	10	12	6.5
13	0.5	8	2000	-1	10	12	6.5
12	1.5	8	2000	-1	10	12	19.5
2	0.5	6	10000	-1	10	10	6.5
10	1.5	6	10000	-1	10	10	19.5
14	0.5	8	10000	-1	10	10	19.5
15	1.5	8	10000	-1	10	10	6.5
11	0.5	6	2000	1	10	20	6.5
17	1.5	6	2000	1	10	20	19.5
26	0.5	8	2000	1	10	20	19.5
18	1.5	8	2000	1	10	20	6.5
22	0.5	6	10000	1	10	20	19.5
20	1.5	6	10000	1	10	20	6.5
21	0.5	8	10000	1	10	20	6.5
1	1.5	8	10000	1	10	20	19.5
8	1	7	6000	0	10	15	13

25	1	7	6000	0	10	15	13
24	0	7	6000	0	10	15	13
19	2	7	6000	0	10	15	13
3	1	5	6000	0	10	15	13
28	1	9	6000	0	10	15	13
9	1	7	2000	0	10	16	13
5	1	7	10000	0	10	15	13
4	1	7	6000	-1	10	12	13
23	1	7	6000	1	10	18	13
6	1	7	6000	0	10	15	4
27	1	7	6000	0	10	15	30

Table C: Conditions for IL-18BP in PEG/(NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>

Run Order	NaCl% [w/w]	pH	PEG Mw	Tie-line	(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub> % [w/w]	PEG% [w/w]	Temp [°C]
7	0.5	6	2000	-1	12	12	19.5
16	1.5	6	2000	-1	12	12	6.5
13	0.5	8	2000	-1	12	12	6.5
12	1.5	8	2000	-1	12	12	19.5
2	0.5	6	10000	-1	12	12	6.5
10	1.5	6	10000	-1	12	12	19.5
14	0.5	8	10000	-1	12	12	19.5
15	1.5	8	10000	-1	12	12	6.5
11	0.5	6	2000	1	20	20	6.5
17	1.5	6	2000	1	20	20	19.5
26	0.5	8	2000	1	20	20	19.5
18	1.5	8	2000	1	20	20	6.5
22	0.5	6	10000	1	20	20	19.5
20	1.5	6	10000	1	20	20	6.5
21	0.5	8	10000	1	20	20	6.5
1	1.5	8	10000	1	20	20	19.5
8	1	7	6000	0	16	16	13
25	1	7	6000	0	16	16	13
24	0	7	6000	0	16	16	13
19	2	7	6000	0	16	16	13
3	1	5	6000	0	16	16	13
28	1	9	6000	0	16	16	13
9	1	7	2000	0	16	16	13
5	1	7	10000	0	16	16	13
4	1	7	6000	-1	12	12	13
23	1	7	6000	1	20	20	13
6	1	7	6000	0	16	16	4
27	1	7	6000	0	16	16	30

Table D: Conditions for IL-18BP in PEG/Na<sub>2</sub>SO<sub>4</sub>

Run Order	NaCl% [w/w]	pH	PEG Mw	Tie-line	Na <sub>2</sub> SO <sub>4</sub> % [w/w]	PEG% [w/w]	Temp [°C]
7	0.5	6	2000	-1	10	10	19.5
16	1.5	6	2000	-1	10	10	6.5
13	0.5	8	2000	-1	10	10	6.5
12	1.5	8	2000	-1	10	10	19.5

2	0.5	6	10000	-1	10	10	6.5
10	1.5	6	10000	-1	10	10	19.5
14	0.5	8	10000	-1	10	10	19.5
15	1.5	8	10000	-1	10	10	6.5
11	0.5	6	2000	1	15	15	6.5
17	1.5	6	2000	1	15	15	19.5
26	0.5	8	2000	1	15	15	19.5
18	1.5	8	2000	1	15	15	6.5
22	0.5	6	10000	1	15	15	19.5
20	1.5	6	10000	1	15	15	6.5
21	0.5	8	10000	1	15	15	6.5
1	1.5	8	10000	1	15	15	19.5
8	1	7	6000	0	12.5	12.5	13
25	1	7	6000	0	12.5	12.5	13
24	0	7	6000	0	12.5	12.5	13
19	2	7	6000	0	12.5	12.5	13
3	1	5	6000	0	12.5	12.5	13
28	1	9	6000	0	12.5	12.5	13
9	1	7	2000	0	12.5	12.5	13
5	1	7	10000	0	12.5	12.5	13
4	1	7	6000	-1	10	10	13
23	1	7	6000	1	15	15	13
6	1	7	6000	0	12.5	12.5	4
27	1	7	6000	0	12.5	12.5	30

Due to the high number of samples generated during this first cycle (3 couples x 28 experiments x 2 phases = 168), purified IL-18BP was used and protein concentration was estimated by UV absorbance at 280 nm. Experiments were 5 performed at 2ml-scale. The response collected was the partition coefficient K defined as:

$$K = \frac{C_{top\_phase}}{C_{bottom\_phase}}$$

Equ 1

### Results

10 The raw data are described in Table E.

**Table E: Results for the first cycle of factorial design experiments**

Run Order	PEG/KH <sub>2</sub> PO <sub>4</sub>	PEG/(NH <sub>4</sub> ) <sub>2</sub> S O <sub>4</sub>	PEG/Na <sub>2</sub> S O <sub>4</sub>
	K <sub>(IL-18BP)</sub>	K <sub>(IL-18BP)</sub>	K <sub>(IL-18BP)</sub>
7	1.5	99.7	12.3
16	0.3	41.1	7.3
13	2.0	289.8	5.9
12	0.6	67.4	3.1
2	1.8	6.1	12.7
10	0.5	8.4	8.7

14	2.9	26.7	5.8
15	2.4	49.0	7.2
11	0.7	97.2	22.0
17	0.5	65.9	37.1
26	2.3	113.1	25.7
18	1.7	170.4	11.5
22	1.1	324.5	101.6
20	0.8	132.8	21.9
21	4.7	78.4	59.8
1	2.3	132.9	32.5
8	1.3	65.3	60.3
25	1.6	3.2	58.9
24	4.0	9.0	49.7
19	0.5	64.0	36.5
3	1.1	72.4	45.4
28	5.7	145.1	129.7
9	0.6	253.7	19.7
5	2.1	129.0	43.6
4	0.8	23.1	8.5
23	1.6	131.2	135.5
6	1.2	48.1	48.7
27	0.5	196.3	94.3

The range of partition coefficient values collected for the three factorial design experiments are illustrated in Table F.

5 **Table F: Range of partition coefficients values obtained after factorial design experiments using  $\text{PEG}(\text{NH}_4)_2\text{SO}_4$ ,  $\text{PEG}/\text{KH}_2\text{PO}_4$  and  $\text{PEG}/\text{Na}_2\text{SO}_4$  phase forming couples.**

	PEG/(\text{NH}_4)_2\text{SO}_4	PEGZ\text{Na}_2\text{SO}_4	PEGZ\text{KH}_2\text{PO}_4
K(IL18-BP)	9.9 - 73.0	4.4 - 163.2	0.2-3.0

10

A statistical analysis was performed on the partitioning of IL-18BP using  $\text{PEGZNa}_2\text{SO}_4$  or  $\text{PEGZKH}_2\text{PO}_4$ . Factors with minor influence on protein partitioning were first eliminated of the statistical analysis. This analysis results in mathematical models (Equ 2 and Equ 3), predictive of the value of K, which takes into consideration the factors found to have significant effects on the response K.

#### Predictive model of IL-18BP partitioning using $\text{PEGZNa}_2\text{SO}_4$

$$\text{LnK(IL18-BP)} = 4.11 + 0.26 \cdot \text{PEGMw} - 0.76 \cdot \text{PEGMw}^2 + 0.81 \cdot \text{TL} - 0.62 \cdot \text{TL}^2 \quad \text{Equ 2}$$

10 R<sup>2</sup>=0.81, SD=0.49

**Predictive model of IL-18BP partitioning using PEG/KH<sub>2</sub>PO<sub>4</sub>**

$$\text{LnK(ZLIS-AP)} = 0.085 - 0.42 \cdot [\text{NaCl}] + 0.31 \cdot \text{PEGMw} + 0.47 \cdot \text{pH} + 0.18 \cdot \text{pH}^2 \quad \text{Equ 3}$$

15 10 R<sup>2</sup>=0.80, SD=0.37

Maximum K values from the predicted model are illustrated in Table G.

**Table G: Maximum partition coefficient K predicted by the model**

	IL-18BP using PEGNa <sub>2</sub> SO <sub>4</sub>	IL-18BP using PEG/KH <sub>2</sub> PO <sub>4</sub>
K	81.5	3.4

15

Second cycle of factorial design experiments

20 The aim of this cycle of factorial design experiments was to select the appropriate conditions (pH, concentrations, etc.) showing extreme protein partitioning and good purification factors. This cycle was performed using PEG/Na<sub>2</sub>SO<sub>4</sub> as phase forming components.

The experimental design was a central composite design. The design included a full two-level factorial, star points, and a centre point, with duplicates at each experimental setting. It resulted to 52 experiments, as shown in Table H.

25 **Table H: Experimental conditions for the second cycle of factorial design experiments**

Run Order	PEG Mw	pH	NaCl% [w/w]	PEG% rw/wl	Na <sub>2</sub> SO <sub>4</sub> % [w/w]
1	6000	9	0	11.25	11.25
2	6000	5	0	13.75	13.75
3	6000	5	0	11.25	11.25
4	6000	9	0	11.25	11.25
5	6000	9	10	13.75	13.75
6	6000	5	10	11.25	11.25
7	6000	9	0	13.75	13.75
8	6000	5	0	11.25	11.25
9	6000	9	10	11.25	11.25
10	6000	7	5	12.50	12.50
11	6000	5	10	11.25	11.25
12	6000	7	5	12.50	12.50
13	6000	9	0	13.75	13.75
14	6000	5	10	13.75	13.75

15	6000	9	10	11.25	11.25
16	6000	5	0	13.75	13.75
17	6000	9	10	13.75	13.75
18	6000	5	10	13.75	13.75
19	8000	7	5	12.50	12.50
20	8000	7	5	12.50	12.50
21	8000	7	5	12.50	12.50
22	8000	7	0	12.50	12.50
23	8000	9	5	12.50	12.50
24	8000	7	5	10.00	10.00
25	8000	7	5	15.00	15.00
26	8000	5	5	12.50	12.50
27	8000	7	5	15.00	15.00
28	8000	7	10	12.50	12.50
29	8000	7	10	12.50	12.50
30	8000	7	5	12.50	12.50
31	8000	7	5	10.00	10.00
32	8000	9	5	12.50	12.50
33	8000	7	0	12.50	12.50
34	8000	5	5	12.50	12.50
35	10000	9	0	11.25	11.25
36	10000	5	0	13.75	13.75
37	10000	9	10	11.25	11.25
38	10000	5	0	11.25	11.25
39	10000	5	0	13.75	13.75
40	10000	7	5	12.50	12.50
41	10000	7	5	12.50	12.50
42	10000	9	0	13.75	13.75
43	10000	9	0	11.25	11.25
44	10000	5	10	11.25	11.25
45	10000	9	0	13.75	13.75
46	10000	9	10	13.75	13.75
47	10000	9	10	11.25	11.25
48	10000	5	10	11.25	11.25
49	10000	5	10	13.75	13.75
50	10000	5	10	13.75	13.75
51	10000	5	0	11.25	11.25
52	10000	9	10	13.75	13.75

Unlike the first cycle of factorial design experiments, clarified crude harvest was used as starting material. Experiments were performed at 10ml-scale. Two responses were collected: the IL-18BP partition coefficient  $K(IL-18BP)$ , related to the capacity of the process, and the total protein partition coefficient  $K_{(tot\_prot)}$  related to the purification ability of the process.

### Results

The raw data are presented in Table I.

**Table 1: Results for the second cycle of factorial design experiments**

Flask	IL-18BP cone [mg/l]			total protein cone [mg/l]			$K_{(totpnot)}$
	Top phase	Bottom phase	$K_{(IL-18BP)}$	Top phase	Bottom phase	$K_{(totpnot)}$	
1	35.5	36.8	0.96	113	9.1	1.24	
2	29.4	51.7	0.57	108	109	0.99	
3	18.4	5.0	0.37	112	101	1.11	
4	34.3	4.4	0.78	104	9.5	1.09	
5	65.1	51.6	1.26	165	6.2	2.66	
6	38.7	64.1	0.60	112	7.3	1.53	
7	127	5.3	23.96	184	2.5	7.36	
8	18.6	58.2	0.32	129	111	1.16	
9	64.2	43.9	1.46	151	5.5	2.75	
10	25.5	83.5	0.31	8.7	115	0.76	
11	26.3	81.7	0.32	8.4	7.9	1.06	
12	26.8	74.6	0.36	8.7	9.7	0.90	
13	74.6	12.5	5.97	147	7.2	2.04	
14	43.8	91.1	0.48	8.7	7.9	1.10	
15	54.1	47.2	1.15	8.7	5.2	1.67	
16	38.2	57.3	0.67	8.9	9.0	0.99	
17	44.6	83.8	0.53	6.9	7.5	0.92	
18	43.1	8.3	0.52	8.8	7.1	1.24	
19	48.1	37.2	1.29	145	6.4	2.27	
20	92.7	4.5	2.06	7.7	7.7	1.00	
21	51.5	45.5	1.13	108	6.6	1.64	
22	34.6	44.8	0.77	102	8.9	1.15	
23	87.1	36.3	2.40	147	8.2	1.79	
24	26.1	64.1	0.41	9.5	9.1	1.04	
25	25.5	5.3	4.81	106	5.6	1.89	
26	61.4	45.2	1.36	147	7.7	1.91	
27	64.1	2.65	24.19	114	5.3	2.15	
28	110	3.3	3.33 ..	195	4.8	4.06	
29	49.5	4.5	1.10	153	6.4	2.39	
30	34.8	51.7	0.67	138	9.9	1.39	
31	26.2	60.4	0.43	103	9.5	1.08	
32	37.5	39.3	0.95	106	7.9	1.34	
33	37.7	53.2	0.71	112	8.3	1.35	
34	31.1	38.9	0.80	106	8.2	1.29	
35	33.6	34.6	0.97	107	8.7	1.23	
36	29.4	27.7	1.06	184	9.3	1.98	
37	4.7	32.1	1.46	161	5.5	2.93	
38	13.3	44.5	0.30	102	9.4	1.09	
39	36.6	23.1	1.58	138	7.4	1.86	
40	27.7	47.4	0.58	125	8.2	1.52	
41	29.8	46.8	0.64	108	8.6	1.26	
42	79.2	8.9	8.90	353	7.0	5.04	
43	23.8	41.7	0.57	118	117	1.01	
44	4.2	42.1	1.00	143	6.7	2.13	
45	62.8	8.02	7.83	191	7.8	2.45	
46	110	11.1	9.91	354	3.7	9.57	
47	61.1	28.8	2.12	217	5.6	3.88	
48	38.4	41.6	0.92	154	6.5	2.37	
49	61.1	23.3	2.62	174	5.1	3.41	

50	86.5	17.4	4.97	271	50	5.42
51	14	47.1	0.30	103	130	0.79
52	70.8	16	4.43	212	65	3.26

The ranges of partition coefficient values observed for the factorial design experiments are illustrated in Table J.

5 **Table J: Range of partition coefficients values for IL-18BP and total proteins obtained by factorial design experiments using PEG/Na<sub>2</sub>SO<sub>4</sub>**

$K_{(IL-18BP)}$	$K_{(tot. prot.)}$
0.3-24.2	0.8-9.6

A statistical analysis was performed on the partitioning of IL-18BP and of total proteins.

In contrast to the first cycle of experiments, the results of this analysis reported in Table

10 K and Table L indicate that all four main factors tested were found significant, as were many second-degree interactions.

**Table K: Output from the quadratic regression model for  $\ln K_{(IL-18BP)}$**

Factor	Value	Std. Err
Intercept	-0.0552	0.1652
[NaCl]	0.0854	0.0886
pH	0.5462	0.0886
PEG Mw	0.3254	0.0886
Tie.line	0.6627	0.0767
[NaCl] <sup>2</sup>	0.3325	0.2254
pH <sup>2</sup>	0.3861	0.2254
(PEG Mw) <sup>2</sup>	-0.6413	0.2254
(Tie-line) <sup>2</sup>	0.2092	0.074
[NaCl]·pH	-0.2428	0.0939
[NaCl]·PEG Mw	0.3163	0.0939
[NaCl]·Tie.line	-0.2988	0.0939
pH·PEG Mw	-0.0921	0.0939
pH·Tie-line	0.1501	0.0939
PEG Mw·Tie-line	0.2287	0.0939

*Residual standard error: 0.5314 on 37 degrees of freedom; Multiple R-Squared:*

15 *0.8312; F-statistic: 13.01 on 14 and 37 degrees of freedom, the p-value is 2.763e-010*

Table L: Output from the quadratic regression model for  $\ln K_{(t_0, t, \text{prot})}$ 

Factor	Value	Std. Err
Intercept	0.2798	0.115
[NaCl]	0.2314	0.0586
pH	0.2023	0.0586
PEG Mw	0.246	0.0586
Tie.line	0.2072	0.0508
NaCl <sup>2</sup>	0.3959	0.1496
pH <sup>2</sup>	0.1639	0.1496
(PEG Mw) <sup>2</sup>	-0.216	0.1496
(Tie-line) <sup>2</sup>	0.0254	0.0496
[NaCl]·pH	-0.044	0.0622
[NaCl]·PEG Mw	0.2048	0.0622
[NaCl]·Tie.line	-0.1369	0.0622
pH·PEG Mw	-0.0468	0.0622
pH·Tie-line	0.087	0.0622
PEG Mw·Tie-line	0.1482	0.0622

Residual standard error: 0.3517 on 36 degrees of freedom; Multiple R-Squared: 0.7351; F-statistic: 7.138 on 14 and 36 degrees of freedom, the p-value is 9.826e-007

5 The predictive models of the second cycle of factorial design experiments allowed the selection of 28 candidate conditions, which show a predicted yield > 75% and a purity in post-A2PS fraction higher than 50%. These are considered as "leads" for further development. The candidate conditions are listed in Table M.

10 Table M: Candidate conditions selected from a statistical analysis of the second cycle of factorial design experiments

Conditions	NaCl% [w/w]	pH	PEG Mw	PEG% [w/w]	Na <sub>2</sub> SO <sub>4</sub> % [w/w]
val2-1	0	5	10000	10	10
val2-2	0	7	10000	10	10
val2-3	10	5	6000	10	10
val2-4	10	7	10000	10	10
val2-5	0	5	10000	11.25	11.25
val2-6	0	7	10000	11.25	11.25
val2-7	10	9	6000	12.5	12.5
val2-8	0	5	6000	10	10
val2-9	0	9	8000	13.75	13.75
val2-10	0	7	6000	15	15
val2-11	0	9	6000	15	15
val2-12	5	9	6000	15	15

val2-13	0	5	8000	15	15
val2-14	5	5	8000	15	15
val2-15	0	7	8000	15	15
val2-16	5	7	8000	15	15
val2-17	0	9	8000	15	15
val2-18	5	9	8000	15	15
val2-19	10	9	8000	15	15
val2-20	0	5	10000	15	15
val2-21	0	7	10000	15	15
val2-22	5	7	10000	15	15
val2-23	0	9	10000	15	15
val2-24	5	9	10000	15	15
val2-25	10	9	10000	15	15
val2-26	10	7	8000	10	10
val2-27	10	5	6000	12.5	12.5
val2-28	10	7	6000	12.5	12.5

Experimental verification of the leads predicted by the predictive model

The aim of these experiments was to verify experimentally the performance of the leads predicted by the statistical analysis. Clarified crude harvest was used as starting material. Experiments were performed at 10ml-scale. Two responses were collected: the IL-18BP partition coefficient  $K_{(IL-18BP)}$ , and the total protein partition coefficient  $K_{(tot)}$ <sub>plot</sub>. Experimental conditions are described in Table M above.

Results

10 Results are reported in Table N. The concentration of IL-18BP was measured by BIACore with an immobilized monoclonal antibody detecting IL-18BP, designated Mab 582.1. IL-18BP concentration was measured by Biacore® method according to the manufacturer's protocol, using the following parameters:

Bulk characterisation	Units	Specification	BULK 1	BULK 2
			7075-035-01 UF2	7075-41-05 UF2
<b>Quantitation</b>				
Protein content	mg/mL; alpha =1.26 at 280nm		0.584	0.171
RP-HPLC	mg/mL		0.586	0.141
<b>Product conformity</b>				
Isoform profile by IEF/WB		cluster of bands falls below pI4.6 as in reference	atypique (cluster below pI 3.5)	atypique (cluster below pI 4.2)
Isoform profile by CZE	%	M0+M1 <30%	M0 = 0%	M0 = 0.6%

			M1 = 13.7%	M1 = 10.3%
	%	M2	M2 = 68.6%	M2 = 71.6%
	%	M3	M3 = 17.7%	M3 = 17.5%
<b>Product based impurities</b>				
Dimers and higher molecular weight (SE-HPLC)	%		92.6	93.3
Dimers and higher molecular weight (SDS/WB)	%		Dimers:8%(28%) Aggregates:0%(15%)	Dimers:0%(33%) Aggregates:0%(n/a)
Truncated forms (SDS/WB)	%		21% (22%)	4% (7%)
<b>Process based impurities</b>				
Cell culture derived protein contaminations (Immunoassay)	ng/mg		51	69
Residual DNA			not performed	not performed

**Table N: Experimental results from the candidate conditions**

Conditions	Balance	IL-18BP	Yield%	Purity% (Biacore/Bradford)
<i>Harvest</i>	<i>B76.B1377.237</i>			<b>40</b>
val2-1	1.07	107		<b>69</b>
val2-2	1.12	112		<b>56</b>
val2-3	1.19	65		<b>93</b>
val2-4	1.08	86		<b>59</b>
val2-5	0.99	98		<b>92</b>
val2-6	0.91	89		<b>59</b>
val2-7	1.16	64		<b>66</b>
val2-8	0.89	54		<b>32</b>
val2-9	0.62	54		<b>55</b>
val2-10	0.18	11		<b>19</b>
val2-11	0.13	11		<b>31</b>
val2-12	0.35	30		<b>43</b>
val2-13	0.10	6		<b>20</b>
val2-14	0.21	19		<b>32</b>
val2-15	0.59	54		<b>42</b>
val2-16	0.91	67		<b>65</b>
val2-17	0.11	8		<b>29</b>
val2-18	1.01	74		<b>74</b>
val2-19	1.01	60		<b>63</b>
val2-20	0.10	7		<b>36</b>
val2-21	0.06	4		<b>18</b>
val2-22	0.34	20		<b>56</b>
val2-23	0.10	4		<b>11</b>
val2-24	0.72	52		<b>36</b>
val2-25	1.00	54		<b>0</b>
val2-26	1.13	75		<b>77</b>

val2-27	1.00	64	97
val2-28	1.04	56	89

Three leads have been identified from the statistical model. Parameters relating to these leads are illustrated in Table O below. The Capillary Zone Electrophoresis (CZE) was carried out according to the following protocol:

5

### Materials and equipment for capillary zone electrophoresis

#### Materials

MilliQ purified water	Millipore or equivalent
10 Trifluoroacetic acid (TFA) cod. 9470	Baker or equivalent
Acetonitrile (CH <sub>3</sub> CN) (Cat. no.30)	Merck or equivalent
NaOH 50% "Baker analyzed" Cat. no.7067	Baker
eCAP™ Phosphate buffer 50 mM, pH 7.0 (Cat. no. 477423)	Beckman Coulter
Interim Reference Material ST1P01/r-hIL-18BP	Serono
15 Neutral marker (Cat. no. 477434)	Beckman Coulter

#### Equipments

P/ACE MDQ System	Beckman Coulter
32 Karat™ software version 4.0	Beckman Coulter
20 eCAP™ Capillary tubing 75µm LD. (Cat. no. 338454)	Beckman Coulter
PCR Vials (Cat. no. 144709)	Beckman Coulter
Micro Vial Springs (Cat. no. 358821)	Beckman Coulter
PCR Vials Caps (Cat. no. 144656)	Beckman Coulter
Vial Holders (Cat. no. 144657)	Beckman Coulter
25 P/ACE System MDQ cartridge (Cat. no 144738)	Beckman Coulter
Sep-Pak Plus tC2 Cartridge (Cat. No. WAT052720)	Waters
Centricon YM-10 (Cat. No. 4206)	Millipore
Millipore	
Millipore or equivalent	
30 1 mL and 5 mL syringes	

#### Solutions for Sep-Pak

Sep-Pak conditioning: 100% CH<sub>3</sub>CN

Sep-Pak equilibrating/washing solution: 25% CH<sub>3</sub>CN in 0.1 % aqueous TFA

35 Sep-Pak eluting solution: 36% CH<sub>3</sub>CN in 0.1 % aqueous TFA (expiration: two weeks at 4°C)

#### Solutions for CZE

5 mM phosphate CZE wash/run buffer

40 Prepare by 1:10 dilution of 50 mM phosphate stock solution pH 7.0. Filter through 0.22 µm filter. Prepare fresh.

0.5 M NaOH (CZE washing solution)

Add 26.2  $\mu$ L 50% NaOH to water, 1 mL total volume. Prepare fresh.

1M NaOH (CZE regeneration solution)

Add 52.4  $\mu$ L 50% NaOH to water, 1 mL total volume. Prepare fresh.

5 Neutral Marker (dilution 1:10000)

Add 10  $\mu$ L neutral marker stock solution to water, 1 mL total volume.

Add 10  $\mu$ L of this neutral marker 1:100 dilution to water, 1 mL total volume.

Store for three months at 4°C.

## 10 METHOD

CZE is a form of high-performance capillary electrophoresis. The capillary is filled with electrolyte buffer and sample separation occurs by applying an electric field across the capillary. The separation mechanism is based on differences in electrophoretic mobility between analytes. Electrophoretic mobility is a function of each analyte's net charge and hydrodynamic size at a given condition.

CZE analysis of samples containing IL-18BP is performed using a CE system with a fused-silica capillary (75  $\mu$ m ID and effective length of 50 cm) filled with a buffer containing 5 mM phosphate.

To increase CZE resolution, the standard Reference and each bulk is desalted by

20 Centricon 10 before CZE analysis. Samples are loaded at about 2.5 mg/mL IL-18BP concentration. Injection into the capillary is performed using a low-pressure injection (=0.5 psi) for 5 seconds. The separation is performed at a constant voltage of 25 KV for  
25 30 minutes at 25°C. The run is monitored using UV absorbance at 284 nm.

For the Reference Standard and bulk samples the procedure consists in two steps:

sample desalting and CZE analysis.

For crude harvest and post-capture samples the high matrix interference is removed to allow observing the IL-18BP glycoprotein profile. In this case, the procedure consists of three steps: a Sep-Pak capture step to remove the high matrix interference, sample desalting, and CZE analysis of captured IL-18BP fraction.

30

### **IL-18BP capture by Sep-Pak procedure for CZE analysis of crude harvest and post-capture samples**

Assemble the Sep-Pak cartridge with a 5 mL syringe, then follow the procedure below:

Table (ii)

Step	Solution	Volume	Eluate
Conditioning (1)	100% CH <sub>3</sub> CN	5 mL	discard

Equilibration (2)	25% CH <sub>3</sub> CN in 0.1 % aqueous TFA	5 mL	discard
Sample loading (3) *		0.5 mL	discard
Washing (4)	25% CH <sub>3</sub> CN in 0.1 % aqueous TFA	5 mL	discard
Elution (5)	36% CH <sub>3</sub> CN in 0.1 % aqueous TFA	0.6 mL	discard
Elution (6)	36% CH <sub>3</sub> CN in 0.1 % aqueous TFA	2.0 mL	Collect **

\* Load up to 500  $\mu$ L of sample having IL-18BP concentration  $\geq$ 250  $\mu$ g/mL. If IL-18BP sample concentration is 70 $\div$ 250  $\mu$ g/mL a higher volume is needed, in this case load any additional up to 500  $\mu$ L sample after 2 mL equilibrating buffer. For diluted samples, concentrate to 500  $\mu$ L by Centricon/Centriflip 10 ultrafiltration at 10 $^{\circ}$ C temperature.

5        \*\* Collect the eluate in a vial containing 1 mL 50 mM Phosphate buffer pH 7.0

The collected solution from step 6 (total volume 3 mL) is concentrated in a Speed-Vac centrifuge to eliminate CH<sub>3</sub>CN and reduce total volume to  $\leq$  2.0 mL.

#### 10      Sample desalting by Centricon 10 ultrafiltration

The Reference Standard, or the bulk or the Speed-Vac solution resulting from the previous step is transferred in Centricon 10 and concentrated to about 100  $\mu$ L by ultrafiltration at 5000  $\times$  g and 10 $^{\circ}$ C.

Desalting is then performed with four 1 mL H<sub>2</sub>O washing at 5000  $\times$  g and 10 $^{\circ}$ C temperature, for 40 minutes each.

Except crude harvest, retentates are diluted and aliquoted (30  $\mu$ L aliquots) at 2.5 mg/mL IL18-BP concentration.

Crude harvest samples are recovered in 40-50  $\mu$ L final volume. This amount is sufficient to prepare two independent CZE samples. The samples are now ready for 20      CZE analysis.

Store all the samples at -20  $^{\circ}$ C up to CZE analysis.

#### CZE analysis

Transfer >20  $\mu$ L sample/reference in PCR vials containing 1/10 volume of neutral

25      marker (3.3.4), mix by reverse pipetting and avoid generating bubbles.

#### *Recommended electrophoretic parameters:*

Add the following reagents into separate vial holders and avoid generating bubbles.

Table (iii)

Inlet reagents	Reagent volume	Outlet reagents	Reagent volume
Wash buffer (3.3.1)	1.2 mL		
Run Buffer (3.3.1)	1.2 mL	Run Buffer (3.3.1)	1.2 mL
Purified water	1.2 mL	Purified water	1.2 mL
CZE washing solution (3.3.2)	1.0 mL		
CZE regenerating solution (3.3.3) *	1.0 mL		
Sample	> 22 $\mu$ L/PCR Vial		
		Waste (purified water) 1	0.2 mL
		Waste (purified water) 2	0.2 mL
Air *	Empty Vial		

\*use only if required

## 5 CZE Analysis time table

Table (iii)

Event	Value	Duration	Inlet Vial	Volume reagent	Outlet Vial
Rinse pressure	20.0 psi	2.00 min	Wash buffer (3.3.1)	1.2 mL	Waste 1 (0.2 mL)
Inject-pressure	0.5 psi	5.0 sec	Sample	$\geq$ 22 $\mu$ L	Run Buffer (3.3.1)
Separate-Voltage	25 KV	30.00 min	Run Buffer (3.3.1)	1.2 mL	Run Buffer (3.3.1)
Rinse pressure	20.0 psi	1.00 min	Wash buffer (3.3.1)	1.2 mL	Waste 1 (0.2 mL)
Rinse pressure	20.0 psi	1.00 min	Purified water	1.2 mL	Waste 1 (0.2 mL)
Rinse pressure	20.0 psi	1.00 min	CZE washing solution (3.3.2)	1.0 mL	Waste 2 (0.2 mL)
Rinse pressure	40.0 psi	2.00 min	Purified water	1.2 mL	Waste 2 (0.2 mL)
Rinse pressure	40.0 psi	2.00 min	Wash buffer (3.3.1)	1.2 mL	Waste 2 (0.2 mL)
Wait			Wash buffer (3.3.1)	1.2 mL	Run Buffer (3.3.1)

## CZE capillary regeneration time table

Table (iv)

Event	Value	Duration	Inlet Vial	Volume reagent	Outlet Vial
Rinse pressure	40.0 psi	1.00 min	Purified water	1.2 mL	Waste 2 (0.2 mL)
Rinse pressure	40.0 psi	10.00 min	CZE regenerating solution (3.3.3)	1.0 mL	Waste 2 (0.2 mL)
Rinse pressure	40.0 psi	4.00 min	Purified water	1.2 mL	Waste 2 (0.2 mL)
Rinse pressure	40.0 psi	1.00 min	Wash buffer (3.3.1)	1.2 mL	Waste 2 (0.2 mL)
Rinse pressure	0.5 psi	30.00 min	Wash buffer (3.3.1)	1.2 mL	Waste 2 (0.2 mL)
Wait			Run Buffer (3.3.1)	1.2 mL	Run Buffer (3.3.1)

	Capillary length to detector/total length	50/60 cm
	Polarity	positive to negative (forward)
	Temperature	capillary = 25±2 C°
5	sample tray	= 10±2 C°
	Detection	214 nm

*Recommended injection protocols*

At least three injections of the Standard Reference material for the purpose of capillary conditioning.

- 10 Standard Reference 1 (start)
- Single injection of sample 1
- Single injection of sample 2
- Single injection of sample 3
- 15 Single injection of sample 4
- Standard Reference 2 (end)

NOTE: To increase reproducibility, a maximum of 4 samples can be analysed in one sequence between reference 1 and reference 2 by using the same CZE running buffer.

20 Alternatively two bracketing references can be used for each sample as described below.

At least three injections of the Standard Reference material are done for the purpose of capillary conditioning.

- Standard Reference (start 1)
- Single injection of sample 1
- Standard Reference (end1/start2)
- Single injection of sample 2
- 5 Standard Reference replicate (end2/start3)
- Single injection of sample 3
- Standard Reference replicate (end3)

*Data Analysis*

- 10 The Standard Reference material is used for comparison of sample data.  
Print the overlaid and stacked electroferograms of sample/s and both bracketing Reference standard (start/end) and archive them in the file results.

*Determination of migration times MT2 and MT3*

- 15 Determine the migration times MT2 and MT3 at the left and right valleys of - 3 and + 3 peaks of the Reference Standard (Start). The 0 peak is the principal peak of the reference.

*Isoforms classification*

- 20 Due the high acidity of IL-18BP glycoprotein profile, the isoforms between MT2 and MT3 are named "*acidic isoforms*". Isoforms with migration times higher then MT3 are named "*highly acidic isoforms*". Isoforms with migration times lower then MT2 are named "*less acidic isoforms*".  
In some circumstances, it might be necessary to add the class of "*basic isoforms*"  
25 defined as isoforms with migration times lower then MT1 .

*Isoforms abundance estimation*

- 30 Analyse the reference and each sample by using the functions: *manual peak* between MT1-M2, MT2-MT3 and MT3-MT4; the *manual baseline* between 5 and 28 minutes and *integration OFF* between 0 and MT1 and between MT4 and 30 minutes. Manually modify the functions *Widthand Treshold* to obtain an integration of three groups of peaks between MT1-M2 (less acidic isoforms), MT2-MT3 (acidic isoforms) and MT3-MT4 (highly acidic isoforms) similar to that showed above for the Reference Standard.

$$\% \text{ isoform abundance} = \frac{\text{area (MT1-MT2 or MT2-MT3 or MT3-MT4)}}{\text{Total area (MT1-MT4)}}$$

When necessary, add the group of peaks corresponding to "*basic isoforms*" defined as  
 5 isoforms with migration times lower than MT1, and accordingly correct the above formula.

### Results of the CZE analysis

The CZE profiles showed that acidic isoforms seemed to be selected by A2PS. The  
 10 results of the isofrom profiles are depicted in Fig. 1.

### Calculation of yield and purity

The yield and purity of the purified IL-18BP were calculated as follows:

Yield:

$$15 \quad Y = \frac{V_{\text{phase}} \cdot C_{\text{phase}}^{\text{IL18BP}}}{V_0 \cdot C_0^{\text{IL18BP}}} \cdot 100$$

Purity

$$\text{Purity} = \frac{C_{\text{phase}}^{\text{IL18BP}}}{C_{\text{phase}}^{\text{tot. prot.}}} \cdot 100$$

$V_{\text{phase}}$ : volume of the phase of interest

20  $C_{\text{phase}}^{\text{IL18BP}}$ : Concentration of IL18BP in the phase of interest

$C_{\text{phase}}^{\text{tot. prot.}}$ : Concentration of total protein in the phase of interest

$V_0$ : volume of the starting material to be purified

$C_0^{\text{IL18BP}}$ : Concentration of IL18BP in the starting material to be purified.

### 25 Results

The parameters measured for the three leads are summarized in Table O. Protein partitioning was reproducible (see standard deviation values). No aggregates were formed during the process.

5 **Table O : Experimental performance of the leads selected from the statistical model for direct capture of IL-18BP using aqueous two-phase system.**

Label	Mass balance	Yield [%]	Purity* [%] (IL-18BP / total proteins)	Aggregates [%] (SDS-PAGE/WB)
IL-18BP				
Starting material:		40	23	
B76.B1 377.237				
Val2-1 (n=3)	1.1 ± 0.07	107 ± 5	69± 5	22
Val2-2 (n=4)	1.1+ 0.10	112 ± 7	56 ± 6	22
Val2-5 (n=4)	1.0 ± 0.05	98 ± 3	92 ± 4	21

\* IL-18BP assay with Biacore, total protein assay with the Bradford method

A2PS process using unclarified harvest.

10 In this section, the direct purification of IL-18BP from crude unclarified harvest was assessed. In order to compare if cells affect the process performance, two process conditions have been compared with and without cells (for process conditions, see Table N).

15 As shown in Table P, process performances were relatively little affected by the presence of cells or cell debris. After phase separation, most of the cells and cell debris were located at a thick interphase.

**Table P: Comparison of process performance using clarified crude harvest and unclarified crude harvest**

Conditions	K(IL-18BP)	K(totplot)
val2-17clarified	8.4	2.7
val2-17 unclarified	13.1	2.6
val2-21 clarified	4.6	1.7
val2-21 unclarified	5.1	2.2
val2-23 clarified	2.5	0.9
val2-23 unclarified	1.8	1.2

val2-25 clarified	1.3	2.9
val2-25 unclarified	1.0	3.3

Optimization of the leads

The aim of these experiments was to optimise the performance of the leads selected previously (Table O). It is possible to optimise the yield, the purity or the concentration

5 factor of the extraction step based on the tie-lines.

*Na<sub>2</sub>S0<sub>4</sub> Concentration*

Conductimetry is commonly used for the determination of salt concentration in A2PS.

However, culture media already contain some salt that can affect the analysis.

10 Therefore, a colorimetric assay (*Kit : Aquanal-plus Sulfate (S0 4)50-330 mg/l (Fluka N° 37429-1EA)*) was used and show better results in that case.

*PEG Concentration*

Refractometry can be used for PEG concentration analysis. However, many culture media components interfere with the analysis. Therefore, size exclusion

15 chromatography was used for PEG concentration analysis under the conditions reported in Table Q.

**Table Q: Conditions for size exclusion chromatography**

<b>Detection</b>	<b>RI</b>
Temperature	40°C
Column	Shodex SB-804
Pressure	30 bars
Flux	0.8 ml/min
Eluent	H <sub>2</sub> O
Injection volume	20 µl
Retention time	26 min.

Tie-lines can be determined by measuring the PEG and Na<sub>2</sub>SO<sub>4</sub> in the top and bottom

20  $K_{(L-18BP)}$  and  $K_{(tot prot)}$  are constant on the same tie-line. Hence, an optimal phase ratio chosen for the purification process would provide a balance between yield and purification factor.

Clarified crude harvest was used as starting material and the experiments were performed at 10ml-scale. Two responses were collected: the IL-18BP partition coefficient  $K_{fL-18BP}$ , and the total protein partition coefficient  $K_{tot,t_{prat}}$ .

5

Results

Four optimised experimental conditions have been tested. Table R summarizes the experimental process performance obtained after partitioning.

10 **Table R: Optimized process conditions based on tie-lines calculation**

Conditions	NaCl% [w/w]	PH	PEG Mw	PEG% fw/w]	Na <sub>2</sub> SO <sub>4</sub> % fw/w]
val2-1 opt1	0	5	10000	28.6	1.9
val2-2 opt1	0	7	10000	28.75	2.25
val2-2 opt2	0	7	10000	21	5.5
val2-5 opt1	0	5	10000	27.9	2.8

Depending on the downstream process and the quality of the final bulk, many more optimised conditions may be selected based on the tie-lines that are shown in Figs. 2, 3 and 4. The flexibility regarding yield, the purity or the concentration factor based on the tie-lines is one of the major advantages of A2PS technology.

15 **Table S: Process performance after optimization of the conditions val2-1, val2-2, val2-5.**

Label	Mass balance	Yield [%]	Concentration factor	Purity* [%]
				(IL-18BP/total proteins)
		Exp	Exp	Exp
Starting material:				47
B76 0007-E				
Val2-1 opt1	0.96	93	14.7	65
Val2-2 opt1	1.04	99	13.3	62
Val2-2 opt2	0.98	98	2.3	81
Val2-5 opt1	0.88	88	6.6	88

\* IL-18BP assay with Biacore, total protein assay with the Bradford method

20

1L-18BP direct capture at 1-liter scale.

The aim of these experiments was to evaluate the major scale-up issues related to A2PS technology. Two conditions from Table R and Table S have been selected for a 100-fold scale up (val2-5; val2-2 opt2). Results are illustrated in Table T. No large 5 differences in process performance can be observed after a 100-fold scale-up.

**Table T: Comparison of process performances at 10 ml-scale and 1000 ml-scale for the conditions val2-5 and val2-2 opt2.**

Label	Mass	Yiel	Purity	Purif	Cone.	Aggregates	CZE			
	balance	d	Biacore/bradfor	.	fact.		Basic	Less acid	Acid	Highly acid
	IL18BP		d	fact.						
Harves r B76 0007-E			40%			21%	5.3	24.3	53.8	16.1
Val2-5 10ml	0.99	98	92%	2.32	1.4	21%	2%	23.9%	56.4%	17.8%
Val2-5 1000 ml	1.12	110	86%	2.15	1.5	21%	2.5%	24.1%	49.1%	24.3%
Val2-2 opt2 10 ml	0.96	93	65%	1.27	14.7	23%	2.8%	21.3%	55.1%	20.8%
Val2-2 opt2 1000 ml	1.06	101	62%	1.27	11.6	27%	3.9%	19.0%	57.7%	19.5%

10

Effect of A2PS process on protein integrity and bulk quality

In order to estimate if direct capture of IL-18BP using A2PS technology affects final bulk quality, post-A2PS-capture material from the scale-up experiment val-2.5 has been purified using further chromatographic purification steps. Results are illustrated in Table 15 U. In comparison with a lot of drug substance obtained with a chromatographic capture

on Fractogel® TMAE (trimethylaminoethyl ion exchange chromatography, purchased from Merck), the lot (7075-41-05 UF2) derived from the A2PS capture shows comparable quality results.

5

**Table U: Bulk characterization after direct capture using A2PS process**

Bulk characterization	Units	Specification	BULK 1	BULK 2
			7075-035-01 UF2	7075-41-05 UF2
<b>Quantification</b>				
Protein content	mg/mL; alpha =1.26 at 280nm		0.584	0.171
RP-HPLC	mg/mL		0.586	0.141
<b>Product conformity</b>				
Isoform profile by IEF/WB		<i>cluster of bands falls below pl4.6 as in reference</i>	atypique (cluster below pl 3.5) *	atypique (cluster below pl 4.2) *
Isoform profile by CZE	%	M0+M1 <30%	M0 = 0% M1 = 13.7%	M0 = 0.6% M1 = 10.3%
	%	M2	M2 = 68.6%	M2 = 71.6%
	%	M3	M3 = 17.7%	M3 = 17.5%
<b>Product based impurities</b>				
Dimers and higher molecular weight (SE-HPLC)	%		92.6	93.3
Dimers and higher molecular weight (SDS/WB)	%		Dimers:8%(28%)** Aggregates:0%(15%)**	Dimers:0%(33%)** Aggregates:0%(n/a)**
Truncated forms (SDS/WB)	%		21% (22%)	4% (7%)
<b>Process based impurities</b>				
Cell culture derived protein contaminations (Immunoassay)	ng/mg		51	69
Residual DNA			not performed	not performed

10 atypique IEF/WB profile due to a too selective CM step. \* Value for the starting material

Conclusions

Table V summarizes the results obtained with traditional chromatographic capture steps shows that A2PS process is simpler; can provide better purity, yield and can be faster.

5

10 **Table V Process performances comparison between different capture steps applied on IL-18BP**

	Q SFF	Fractogel TMAE HiCap	A2PS
Load condition	UF/DF needed	UF/DF needed	Direct capture
Yield	89%	91%	98%
Purity (ELISA/Bradford)	46%	42%	72%
Run times	720 min	360 min	240 min

REFERENCES

1. Ageland, H., Nystrom, L., Persson, J., and Tjerneld, F. Process for purifying a protein. (US 6559284). 2003. Esperion Therapeutics, Inc. (Ann Arbor, MI).
2. Altschul S F et al, J Mol Biol, 215, 403-410, 1990
- 5 3. Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997
4. Ananthapadmanabhan, K. P. and Goddard, E. D. (US 4743550). 1988. ( to Union Carbide Corporation).
5. Balasubramaniam, D., Wilkinson, C , van Cott, K., & Zhang, C. (2003) *Journal of Chromatography A* 989, 119.
- 10 6. Bamberger, S., Brooks, D.E., Sharp, K.A., van Alstine, J.M., & Webber, T.J. (1985) in *Partitioning in Aqueous Two-Phase Systems: Theory, Methods, Uses, and Applications to Biotechnology* (Walter, H., Brooks, D.E., & Fisher, D., Eds.) pp 85Academic Press, Orlando, Fla.
7. Baskir, J.N., Hatton, T.A., & Sutter, V.W. (1987) *Macromolecules* 20, 1300.
- 15 8. Baskir, J.N., Hatton, T.A., & Sutter, V.W. (1989) *Biotechnol.Bioeng.* 34, 541.
9. Bierau, H., Hinton, R.J., & Lyddiatt, A . (2001) *Bioseparation*.
10. Bleier, J.E., Kim, E.H., & Chen, X.D. (2001) *Biotechnol.Prog.* 17, 697.
11. Bompensieri, S., Malher, G.F., Castaneda, N., Miranda, M.V., Cascone, O., & Nudel, B.C. (1998) *Biotechnology Techniques* 12, 611.
- 20 12. Boschetti, E., Jungbauer, Sep. ScL & Tech. 2 No. 15, Acad. Press (2000) 53
13. Boschetti et al., Genetic Engineering Vol. 20, No. 13, July, 2000
14. Braunstein, E. L., Becker, N. T., anshaw, G., and raycar, T. P. (WO 96/23061). 1995. (to Genencor International, Inc.).
15. Brewer, J. W., Brothers, C. E., Farver, T. F., im, C. Y., and ee, E. (US 4728613). 25 1988. (to Miles Laboratories, Inc.).
16. Builder, S. E., Hart, R. A., Lester, P. M., Ogez, J. R., and Reifsnyder, D. H. (US 5407819). 1995. (to Genentech, Inc.).
17. Cordes, A. & Kula, M.R. (1994) *Methods Enzymol* 228, 600.
18. Costa, M.J., Cunha, M.T., Cabral, J.M., & Aires-Barros, M.R. (2000) 30 *Bioseparation* 9, 231.
19. Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984.
20. Diamond, A.D., Yu, K., & Hsu, JT. (1990) *ACS Symposium Series* 427, 52.

21. Dos Reis Coimbra, J., Thömmes, J., & Kula, M.R. (1994) *Journal of Chromatography A* 668, 85.

22. Dove, G. B and Mitra, G. (US 4684723). 1988. (to Miles Laboratories, Inc).

23. Duarte, M., Portugal, E.P., Ponezi, A.N., Bim, MA, Tagliari, C.V., & Franco, TT. (2003) *Bioresource Progress* 68, 49.

5 24. Eitman, M.A. & Gainer, J.L. (1990) *Biotechnol.Prog.* 6, 479.

25. Eitman, MA & Gainer, J.L. (1991) *Bioseparation* 2, 31.

26. Enfors, S. O., Kölher, K., Ljundquist, Ch., Nilsson, B., and Veide, A. (WO 92/07868). 1992. (Pharmacia AB, Sweden).

10 27. Femandes, S., Kim, H.S., & Hatti-Kaul, R. (2002) *Protein Expr.Purif.* 24, 460.

28. Grantham et al., Science, Vol. 185, pp. 862-864 (1974)

29. Guan, Y., Wu, S.Y., Treffy, E., & Hey, T.H. (1992) *Biotechnol.Bioeng.* 40, 517.

30. Giuliano, K. A. and Szlag, D. C. (US 5093254). 1992. (to the United States).

15 31. Guinn, M. R. Aqueous two-phase metal affinity partitioning protein purification system. (US 5907035). 1997. (to Baxter Biotech Technology Sari, Neuchatel, CH).

32. Guoqiang, D., Kaul, R., & Mattiasson (1994) *Journal of Chromatography A* 668, 145.

33. Gustafsson, S. J., Hedman, P. O., Ling, T. G. I., and Mattiasson, B. G. (US 20 4579661). 1986. (to Pharmacia AB, Sweden).

34. Hart, R.A., Lester, P.M., Reifsnyder, D.H., Ogez, J.R., & Builder, S.E. (1994) *Biotechnology (N Y)* 12, 113.

35. Hatti-Kaul, R. (2000) in *Aqueous Two-Phase Systems: Methods and Protocols*, Humana Press, Totowa, New Jersey.

25 36. Hayenga, K. J., Valax, and P.P. Methods for protein purification using aqueous two-phase extraction. (US 6437101). 1999. (to Akzo Nobel N.V., Arnhem, NL).

37. Haynes, C.A., Beynon, R.A., King, R.S., Blanch, H.W., & Prausnitz, J.M. (1989a) *Journal of Physical Chemistry* 93, 5612.

38. Haynes, C.A., Blanch, H.W., & Prausnitz, J.M. (1989b) *Fluid Phase Equilibria* 53, 463.

30 39. Heinsohne, H. G. and Hayenga, K. J. (EU 0 477284 B1). 1995. ( to Smithkline Biologicals).

40. Heinsohne, H. G., Lorch, J. D., and Arnold, R. E. (US 5139943). 1992. (to Genecor International, Inc.).

41. Johansson, G. & Reczey, K. (1998) *Journal of Chromatography B* 711, 161.

42. Kim, C. Y., Farver, T. F., and Brewer, J. W. (US 4508825). 1985. ( to Miles Laboratories, Inc.).

5 43. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, Dinarello CA. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A 2000;97:1190-1195.

10 44. King, R.S., Blanch, H.W., & Prausnitz, J.M. (1988) *American Institute of Chemical Engineers Journal* 34, 1585.

45. Kirchberger, J., Kopperschlager, G., Rockstroh, M., and Eisenbrandt, K. (DD 298 424). 1992. (to Universitat Leipzig, Germany).

46. Lee, C. J. and Khan, P. (US 5407579). 1995. (to National Science Concil, 15 Taipei).

47. Li, Y. & Beitle, R.R. (2002) *Biotechnol.Prog.* 18, 1054.

48. Lorch, J. D., Clarkson, E., Larenas, B. S., Bower, B. S, and Weiss, G. L. (US 5328841). 1994. (to Genecore International, Inc.).

49. Menge, U., Fraune, E., Lehmann, J., & Kula, M.R. (1987) *Dev Biol Stand* 66, 20 »391.

50. Menge, U., Morr, M., and Kula, M. R. (DE 2943026 C2). 1984. ( to the Gesellschaft fur Biotechnologische Forschung mbH).

51. Minami, N.M. & Kilikian, B.V. (1997) *Journal of Chromatography* 711, 309.

52. Novick, D, Kim, S-H, Fantuzzi, G, Reznikov, L, Dinarello, C, and Rubinstein, M 25 (1999). *Immunity* 10, 127-136.

53. Paul, F., Monsan, P., and Auriol, D. (US 4591563). 1986. (to Societe Nationale Elf Aquitaine, France).

54. Pearson, Methods Enzymol. 1990;183:63-98

55. Persson, J., Johasson, H.O., & Tjerneld, F. (1999) *Journal of Chromatography* 30 /1864, 31.

56. J. Porath, J. Carlsson, I. Olsson, and G. Belfrage, *Nature (London)* 258, 598-599 (1975)

57. J. Porath and B. OHn, *Biochemistry* 22, 1621-1630 (1983)

58. Puren et al., *Proc Natl Acad Sci U S A*. 1999 Mar 2;96(5):2256-61 .

59. Schütte, H., Hummel, W., & Kula, M.R. (1984) *Applied Microbiology and Biotechnology* 19, 167.

60. Schütte, H., Hummel, W., Tsai, H., & Kula, M.R. (1985) *Applied Microbiology and Biotechnology* 22, 306.

61. Sieron, R., Wondraczeck, R., Binder, K, Dittmar, H., Lambrecht, K., and Thessa, H. (DD 288837). 1994. (to Zentralinstitut fur Mikrobiologie und experimentelle Therapie).

62. Suzuki, M., Kamihira, M., Shiraishi, T., Takeuchi, H., & Kobayashi, T. (1995) *Journal of Fermentation and Bioengineering* 80, 78.

10 63. Tjerneld, F. & Johansson, G. (1987) *Biotechnol.Bioeng.* 30, 809-816.

64. Tjerneld, F., Persson, J., and Johansson, H. O. Separation method utilizing liquid-liquid partition. (US 6454950). 2002. (to Amersham Pharmacia Biotech AB, Uppsala, SE).

15 65. Urushihara, J *Pediatr Surg.* 2000 Mar;35(3):446-9.

66. van Wijnendaele, F., Gilles, D., and Simonet, G. (EU 0199698 B1). 1991. ( to Smithkline Biologicals S.A.).

67. Vigers et al., *Nature*. 1997 Mar 13;386(6621): 190-4.

20 68. Walter, H., Brooks, D.E., & Fisher, D. (1985) in *Partitioning in Aqueous Two-Phase Systems: Theory, -Methods, Uses, and Applications to Biotechnology*, Academic Press, Orlando, Fla.

69. Zaslavsky, B.Y. (1995b) in *Aqueous Two-Phase Partitioning* (Zaslavsky, B.Y., Ed.) pp 503-667, Marcel Dekker, Inc, New York, Basel, Honk Hong.

25 70. Zaslavsky, B.Y. (1995a) in *Aqueous Two-Phase Partitioning* (Zaslavsky, B.Y., Ed.) pp 75-152, Marcel Dekker, Inc, NEw York, Basel, Honk Hong.

CLAIMS

1. A process for purifying IL-18BP from a fluid comprising at least one step using  
5 aqueous two-phase partitioning.
2. The process according to claim 1, wherein the aqueous two-phase system  
comprises a polyethylene glycol (PEG) phase and a salt phase.
- 10 3. The process according to any of the preceding claims, wherein PEG has a  
molecular weight ranging between about 2'000 and about 12000.
4. The process according to any of the preceding claims, wherein PEG has a  
molecular weight of about 10'000.
- 15 5. The process according to any of the preceding claims, wherein the salt phase  
comprises  $(\text{NH}_4)\text{SO}_4$ .
6. The process according to claim 1 to 5, wherein the salt phase comprises  $\text{KH}_2\text{PO}_4$ .
- 20 7. The process according to any of claims 1 to 4, wherein the salt phase comprises  
 $(\text{Na}_2)\text{SO}_4$ .
8. The process according to claim 7, wherein the initial concentration of  $(\text{Na}_2)\text{SO}_4$  is  
25 less than about 20 % [w/w] or about 14% [w/w] or about 12% [w/w] or about 10%  
[w/w] or about 8% [w/w] or about 6% [w/w] or about 4% [w/w] or about 2% [w/w]
- 30 9. The process according to any of the preceding claims, wherein PEG is used at a  
concentration of less than about 35% [w/w] or about 30% [w/w] or about 25 %  
[w/w] or about 20% [w/w] or about 15% [w/w] or about 12 % [w/w] or about 10 %  
[w/w] or about 5% [w/w].

10. The process according to any of the preceding claims, wherein the concentrations of the two phases are calculated according to the following formula:

$$y = -2.5108x + 35.159$$

5           wherein y = PEG in % [w/w] and x =  $(\text{Na}_2)\text{SO}_4$  in % [w/w].

11. The process according any of claims 1 to 9, wherein the concentrations of the two phases are calculated according to the following formula:

$$y = -2.5573X + 35.757$$

10           wherein y = PEG in % [w/w] and x =  $(\text{Na}_2)\text{SO}_4$  in % [w/w].

12. The process according to any of claims 1 to 9, wherein the concentrations of the two phases are calculated according to the following formula:

$$y = -2.1182x + 35.355$$

15           wherein y = PEG in % [w/w] and x =  $(\text{Na}_2)\text{SO}_4$  in % [w/w].

13. The process according to any of the preceding claims, wherein the process is carried out at a pH ranging between pH 4 and 9.

20           14. The process according to claim 13, wherein it is carried out at about pH 5.

15. The process according to claim 13, wherein it is carried out at about pH 7.

25           16. The process according to any of the preceding claims, wherein the process is carried out at room temperature.

17. The process according to any of the preceding claims, wherein the step using an aqueous two-phase system is a capture step.

30           18. The process according to any of the preceding claims, further comprising one or more additional purification steps.

19. The process according to claim 18, wherein the additional purification steps are selected from metal ion affinity chromatography, hydrophobic interaction chromatography, ion exchange chromatography and reverse phase chromatography.

5

20. The process according to any of the preceding claims, further comprising one or more ultrafiltration steps.

10 21. The process according to any of the preceding claims, further comprising one or more virus removal filtration steps.

15 22. The process according to any of the preceding claims, wherein the fluid is selected from cell culture harvest, cell lysate, cell extract, tissue extract, blood plasma, serum, milk, urine, ascites, plant extract, or a fraction derived from an earlier protein purification step.

23. The process according to claim 22, wherein the cell culture harvest is unclarified crude cell culture harvest.

20 24. The process according to claim 22, wherein the cell culture harvest is clarified crude cell culture harvest.

25 25. The process according to any of claims 22 to 24, wherein the cell culture harvest is derived from Chinese Hamster Ovary (CHO) cells.

26. The process according to claim 25, wherein the CHO cells are grown in suspension.

30 27. The process according to any of the preceding claims, wherein the IL-18BP is human, recombinant IL-18BP.

28. A protein preparation comprising IL-18BP obtained by a process according to any of the preceding claims.

29. Use of an aqueous two-phase system for the purification of IL-18BP

30. Use of an aqueous two-phase system for the capture of IL-18BP from a fluid.




Fig. 1

2/3






Fig. 2

Fig. 3





# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2005/053010

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07K1/14 C07K1/20 C07K14/715

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and where practical, search terms used)

EPO-Internal , BIOSIS, WPI Data, PAJ, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category <sup>o</sup>	Citation of document with indication where appropriate, of the relevant passages	Relevant to claim No
X	WO 99/09063 A (RUBINSTEIN MENACHEM , KIM SOO HYUN (IL); NOVICK DANIELA (IL); YEDA RES) 25 February 1999 (1999-02-25) cited in the application page 34, line 1 - line 14 -----	28
X	EP 1 110 969 A (HAYASHIBARA BIOCHEM LAB) 27 June 2001 (2001-06-27) example 1.1 -----	28
A	CORDES A ET AL: "Large-scale purification of formate dehydrogenase." METHODS IN ENZYMOLOGY. 1994, vol. 228, 1994, pages 600-608, XP009038142 ISSN: 0076-6879 cited in the application the whole document ----- -/-	1-30

Further documents are listed in the continuation of box C

Patent family members are listed in annex

<sup>o</sup> Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

21 October 2005

28/10/2005

Name and mailing address of the ISA

European Patent Office, P B 5818 Patentlaan 2  
NL- 2280 HV RISWIJK  
TeI (+31-70) 340-2040, Tx 31 651 epo nl  
Fax (+31-70) 340-3016

Authorized officer

Weikl , M

**INTERNATIONAL SEARCH REPORT**

International Application No

PCT/EP2005/053010

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	wo 00/68260 A (COVANCE BIOTECHNOLOGY SERVICES) 16 November 2000 (2000-11-16) cited in the application the whole document -----	1-30
A	HATTI-KAUL RAJNI : "Aqueous two-phase systems : A general overview" MOLECULAR BIOTECHNOLOGY, vol. 19, no. 3, November 2001 (2001-11) , pages 269-277, XP009038161 ISSN: 1073-6085 the whole document -----	1-30

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP2 005/053010

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
wo 9909063	A 25-02-1999	AU 755794	B2	19-12-2002
		AU 8746098	A	08-03-1999
		BG 104149	A	31-08-2000
		BR 9811940	A	05-09-2000
		CA 2298855	AI	25-02-1999
		CN 1267307	A	20-09-2000
		DE 1003781	TI	11-01-2001
		EA 3675	BI	28-08-2003
		EE 200000073	A	16-10-2000
		EP 1003781	AI	31-05-2000
		HU 0003533	A2	29-01-2001
		JP 2001514876	T	18-09-2001
		NO 20000700	A	14-04-2000
		NZ 502392	A	20-12-2002
		PL 338647	AI	06-11-2000
		SK 1762000	A3	12-09-2000
		US 6605280	BI	12-08-2003
-----	-----	-----	-----	-----
EP 1110969	A 27-06-2001	BR 9816013	A	21-01-2003
		CA 2340579	AI	09-03-2000
		wo 0012555	AI	09-03-2000
-----	-----	-----	-----	-----
wo 0068260	A 16-11-2000	AU 777974	B2	04-11-2004
		AU 4703600	A	21-11-2000
		BR 0010707	A	04-06-2002
		CA 2372513	AI	16-11-2000
		EP 1194445	AI	10-04-2002
		OP 2002544139	T	24-12-2002
		MX PA01011356	A	20-08-2003
		NZ 515381	A	31-10-2003
		US 6437101	BI	20-08-2002
-----	-----	-----	-----	-----